CA2821613A1 - Preparation comprising insulin, nicotinamide and an amino acid - Google Patents
Preparation comprising insulin, nicotinamide and an amino acid Download PDFInfo
- Publication number
- CA2821613A1 CA2821613A1 CA2821613A CA2821613A CA2821613A1 CA 2821613 A1 CA2821613 A1 CA 2821613A1 CA 2821613 A CA2821613 A CA 2821613A CA 2821613 A CA2821613 A CA 2821613A CA 2821613 A1 CA2821613 A1 CA 2821613A1
- Authority
- CA
- Canada
- Prior art keywords
- insulin
- preparation according
- insulin preparation
- arginine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 911
- 102000004877 Insulin Human genes 0.000 title claims abstract description 463
- 108090001061 Insulin Proteins 0.000 title claims abstract description 463
- 229940125396 insulin Drugs 0.000 title claims abstract description 456
- 238000002360 preparation method Methods 0.000 title claims abstract description 431
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title claims description 62
- 235000005152 nicotinamide Nutrition 0.000 title claims description 31
- 239000011570 nicotinamide Substances 0.000 title claims description 31
- 229960003966 nicotinamide Drugs 0.000 title claims description 31
- 150000001413 amino acids Chemical class 0.000 title abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 84
- -1 insulin compound Chemical class 0.000 claims abstract description 42
- 239000004475 Arginine Substances 0.000 claims description 93
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 93
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 69
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 67
- 238000011282 treatment Methods 0.000 claims description 43
- 239000011701 zinc Substances 0.000 claims description 38
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 36
- 229910052725 zinc Inorganic materials 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 32
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 239000003755 preservative agent Substances 0.000 claims description 25
- 239000000872 buffer Substances 0.000 claims description 22
- 206010012601 diabetes mellitus Diseases 0.000 claims description 22
- 239000004026 insulin derivative Substances 0.000 claims description 21
- 201000001421 hyperglycemia Diseases 0.000 claims description 18
- 229960003512 nicotinic acid Drugs 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 239000007983 Tris buffer Substances 0.000 claims description 16
- 208000027418 Wounds and injury Diseases 0.000 claims description 16
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 15
- 229910021645 metal ion Inorganic materials 0.000 claims description 15
- 239000011664 nicotinic acid Substances 0.000 claims description 15
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 230000001195 anabolic effect Effects 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 13
- 235000001968 nicotinic acid Nutrition 0.000 claims description 13
- 239000008363 phosphate buffer Substances 0.000 claims description 13
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- 239000003381 stabilizer Substances 0.000 claims description 11
- 208000028399 Critical Illness Diseases 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 10
- 208000014674 injury Diseases 0.000 claims description 10
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 206010052428 Wound Diseases 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 208000029078 coronary artery disease Diseases 0.000 claims description 6
- 229930003537 Vitamin B3 Natural products 0.000 claims description 5
- 235000019160 vitamin B3 Nutrition 0.000 claims description 5
- 239000011708 vitamin B3 Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 abstract description 16
- 229960003121 arginine Drugs 0.000 description 85
- 235000009697 arginine Nutrition 0.000 description 85
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 82
- 108010073961 Insulin Aspart Proteins 0.000 description 35
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
- 229960004717 insulin aspart Drugs 0.000 description 23
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 20
- 235000002639 sodium chloride Nutrition 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical group [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- WEDIKSVWBUKTRA-WTKGVUNUSA-N CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC WEDIKSVWBUKTRA-WTKGVUNUSA-N 0.000 description 17
- 239000007857 degradation product Substances 0.000 description 16
- 238000005755 formation reaction Methods 0.000 description 15
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 15
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 14
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000009102 absorption Effects 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 239000011550 stock solution Substances 0.000 description 13
- 238000005259 measurement Methods 0.000 description 12
- 230000002335 preservative effect Effects 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 239000004094 surface-active agent Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 239000000825 pharmaceutical preparation Substances 0.000 description 11
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 210000004899 c-terminal region Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 241000282887 Suidae Species 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 229960005150 glycerol Drugs 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 235000013922 glutamic acid Nutrition 0.000 description 7
- 229960002989 glutamic acid Drugs 0.000 description 7
- 239000004220 glutamic acid Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 150000002989 phenols Chemical class 0.000 description 7
- 238000010254 subcutaneous injection Methods 0.000 description 7
- 239000007929 subcutaneous injection Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 206010061592 cardiac fibrillation Diseases 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000002600 fibrillogenic effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 239000012929 tonicity agent Substances 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000002144 chemical decomposition reaction Methods 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001483 arginine derivatives Chemical class 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000010030 glucose lowering effect Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229930003836 cresol Natural products 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Chemical compound CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FVIGODVHAVLZOO-UHFFFAOYSA-N Dixanthogen Chemical compound CCOC(=S)SSC(=S)OCC FVIGODVHAVLZOO-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010076181 Proinsulin Proteins 0.000 description 2
- 229940123452 Rapid-acting insulin Drugs 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 108010026951 Short-Acting Insulin Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 2
- 230000001925 catabolic effect Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000004246 zinc acetate Substances 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- 102000001049 Amyloid Human genes 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- RVEWUBJVAHOGKA-WOYAITHZSA-N Arginine glutamate Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N RVEWUBJVAHOGKA-WOYAITHZSA-N 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 101710163305 Fibril protein Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000380126 Gymnosteris Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 229960004246 arginine glutamate Drugs 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000007681 bariatric surgery Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 206010066336 critical illness polyneuropathy Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940006445 isophane insulin Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000003717 m-cresyl group Chemical group [H]C1=C([H])C(O*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108010066381 preproinsulin Proteins 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229960000957 prothipendyl Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000930 thermomechanical effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000007056 transamidation reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.
Description
PREPARATION COMPRISING INSULIN, NICOTINAMIDE AND AN AMINO ACID
FIELD OF THE INVENTION
The present invention relates to pharmaceutical preparations comprising an insulin com-BACKGROUND OF THE INVENTION
Diabetes mellitus is a metabolic disorder in which the ability to utilize glucose is partly or completely lost. About 5% of all people suffer from diabetes and the disorder approaches ep-idemic proportions.
Since the introduction of insulin in the 1920's, continuous improvements have been made in the treatment of diabetes. To help avoid high glycaemia levels, diabetic patients of-ten practice multiple injection therapy, whereby insulin is administered with each meal. As diabetic patients have been treated with insulin for several decades, there is a major need for safe and life-quality improving insulin preparations. Among the commercially available insulin In the treatment of diabetes mellitus, many varieties of pharmaceutical preparations of insulin have been suggested and used, such as regular insulin (such as Actrapide), isophane insulin (designated NPH), insulin zinc suspensions (such as Semilente , Lente , and Ul-International applications WO 91/09617 and WO/9610417 (Novo Nordisk NS) disclose insu-lin preparations containing nicotinamide or nicotinic acid or a salt thereof.
European applica-tion EP1283051 allegedly discloses insulin preparation containing arginine, where arginine is used as buffering agent. EP1283051 allegedly discloses improvement of physical stability of Most often pharmaceutical preparations of insulins are administered by subcutane-ous injection. Important for the patient is the action profile of the insulin, meaning the action of insulin on glucose metabolism as a function of time from injection. In this profile, inter alia, the time of the onset, the maximum value and the total duration of action are important. In the case of bolus insulins, a variety of insulin preparations with different action profiles are desired and requested by the patients. One patient may, on the same day, use insulin prepa-rations with very different action profiles. The action profile desired for example, depends on the time of the day and the amount and composition of the meal eaten by the patient.
Equally important for the patient is the chemical stability of the insulin preparations, for example, due to the abundant use of pen-like injection devices such as devices which contain Penfill cartridges, in which an insulin preparation is stored until the entire cartridge is empty which may be at least 1 to 2 weeks for devices containing 1.5-3.0mIcartridges. During storage, covalent chemical changes in the insulin structure occur. This may lead to formation of molecules which may be less active and/or potentially immunogenic such as deamidation products and higher molecular weight transformation products (dimers, polymers). Further-more, also important is the physical stability of the insulin preparations, since long term stor-age may eventually lead to formation of insoluble fibrils, which are biologically inactive and potentially immunogenic.
SUMMARY OF THE INVENTION
The invention relates to insulin preparations with favourable absorption rate and favourable chemical and physical stability. The present invention relates to insulin preparations compris-ing human insulin and/or analogues thereof, nicotinamide or nicotinic acid and/or salts there-of and arginine.
In one embodiment, the present invention relates to an insulin preparation comprising:
= an insulin compound, = a nicotinic compound, and = arginine.
In another embodiment, the present invention also contemplates a method for the treatment of diabetes mellitus in a subject or for reducing the blood glucose level in a subject compris-ing administering to a subject or mammal an insulin preparation according to the invention.
DESCRIPTION OF THE DRAWINGS
Figure 1 shows the development in percentage of total insulin content of degradation prod-ucts during 2 weeks of storage at 37 C of preparations according to the present invention.
The letter A refers to a NovoRapid reference and remaining letters correspond to insulin as-part preparations as described in Table 1 of Example 1. Compared to the NovoRapid prep-aration (preparation A), addition of nicotinamide (preparations B and D) leads to an in-creased formation of degradation products, whereas the combined addition of nicotinamide, glutamic acid and arginine (preparations C and E), has a mostly similar degradation pattern, with lower formation of HMWP.
Figure 2 shows the development in percentage of total insulin content of degradation prod-ucts during 2 weeks of storage at 37 C of preparations according to this invention. The letter A refers to a NovoRapid reference and remaining letters correspond to insulin aspart prepa-rations as described in Table 1 of Example 1. The combined addition of nicotinamide, glu-tamic acid and arginine, preparations F, G, H, and I, differing in buffer system, phosphate or tris buffer, and concentration of insulin and Zn, 0.6mM and 0.3mM or 1.2mM and 0.6mM, has a degradation pattern similar to the NovoRapid preparation, preparation A.
Figure 3 shows the glucose concentration (mean +/- SEM, N=8) in plasma after subcutane-ous injection in pigs of a lnmol/kg dose at 0 minutes of preparations according to this inven-tion. The letter A refers to a NovoRapid reference and remaining letters correspond to insu-lin aspart preparations as described in Table 1 of Example 1. Compared to the NovoRapid preparation (preparation A) the initial rate of plasma glucose lowering is faster for the prepa-ration with addition of nicotinamide (preparation N) and even faster for a combination of nico-tinamide and arginine (preparation M).
Figure 4 shows the glucose concentration in plasma (mean +/- SEM, N=7) after subcutane-ous injection in pigs of a lnmol/kg dose at 0 minutes of preparations according to this inven-tion. The letter A refers to a NovoRapid reference and remaining letters correspond to insu-lin aspart preparations as described in Table 1 of Example 1. Compared to the NovoRapid preparation (preparation A), the initial rate of plasma glucose lowering is faster for a prepara-tion with a combination of nicotinamide, arginine and glutamic acid (preparation L) and for a preparation with a combination of nicotinamide and arginine (preparation K).
Figure 5 shows the insulin aspart concentration in plasma (mean +/- SEM, N=7) after subcu-taneous injection in pigs of a 1 nmol/kg dose at 0 minutes of preparations according to this invention. The letter A refers to a NovoRapid reference and remaining letters correspond to insulin aspart preparations as described in Table 1 of Example 1. Compared to the No-voRapid preparation, (preparation A) , the initial absorption rate of the insulin component of the preparations with nicotinamide (preparation J), the combination of nicotinamide and ar-ginine (preparation K), and the combination of nicotinamide, arginine and glutamic acid (preparation L) is markedly faster.
Figure 6 shows the glucose concentration in plasma (mean +/- SEM, N=8, each pig dosed twice) after subcutaneous injection in pigs of a lnmol/kg dose at 0 minutes of preparations according to this invention. The letter A refers to a NovoRapid reference and number 11 corresponds to a insulin aspart preparation as described in Table 3 of Example 1. Compared to the NovoRapid preparation (preparation A), the initial rate of plasma glucose lowering is faster for a preparation with a combination of nicotinamide and arginine (preparation 11).
Figure 7 shows the insulin aspart concentration in plasma (mean +/- SEM, N=8, each pig dosed twice) after subcutaneous injection in pigs of a 1 nmol/kg dose at 0 minutes of prepa-rations according to this invention. The letter A refers to a NovoRapid reference and number 11 corresponds to a insulin aspart preparation as described in Table 3 of Example 1. Com-pared to the NovoRapid preparation (preparation A), the initial absorption rate of the insulin component of the preparations with nicotinamide and arginine (preparation 11) is markedly faster.
DESCRIPTION OF THE INVENTION
The absorption after subcutaneous injection of the insulin compound in the insulin prepara-tions of the present invention was surprisingly found to be faster than that of the reference insulin preparations. This property is useful for rapid-acting insulins, in particular in connec-tion with a multiple injection regimen where insulin is given before each meal. With faster on-set of action, the insulin can conveniently be taken closer to the meal than with conventional rapid acting insulin solutions. Furthermore, a faster disappearance of insulin probably dimin-ishes the risk of post-meal hypoglycaemia.
The insulin preparations of the present invention are rapid-acting insulin prepara-tions comprising an insulin compound such as insulin aspart, a nicotinic compound, such as nicotinamide and the amino acid arginine. Optionally, the insulin preparations of the present invention may comprise further amino acids. These insulin preparations have a rapid absorp-tion profile that mimics normal physiology more closely than existing therapies. Furthermore, the insulin preparations of the present invention have chemical and physical stability suitable for commercial pharmaceutical preparations.
The insulin preparations of the present invention provide fast-acting insulin prepara-tions which are not only physically stable, but surprisingly also chemically stable. The insulin preparations of the present invention provide an even faster onset of action compared with existing insulin therapies. Such ultra-fast insulin preparations have the advantage of restoring 5 first phase insulin release, injection convenience and shutting down hepatic glucose produc-tion. The insulin preparations of the present invention have a favourable absorption rate from subcutis into plasma with an increase in initial absorption rate ranging from 1.5 to 5 times, when compared to conventional preparations such as NovoRapid , as suggested by several PK/PD experiments in pigs. This faster absorption rate may improve glycaemic control and convenience and may allow for a shift from pre-meal to post-meal dosing. The present inven-tion is based in part, on the surprising discovery that although, the addition of nicotinamide allows the increase in absorption rate, it also has a negative effect on chemical stability by significantly increasing the amount of HMWP. The insulin preparations of the present inven-tion have an improved chemical stability by addition of arginine, which is reflected in e.g. a reduction in the formation of dimers and polymers and desamido insulins after storage. The insulin preparations of the present invention may furthermore also have improved physical stability, which may be useful for use in pumps.
The present invention provides an insulin preparation comprising an insulin com-pound according to the present invention which is present in a concentration from about 0.1 mM to about 10.0mM, and wherein said preparation has a pH from 3 to 8.5. The preparation also comprises a nicotinic compound and arginine. The preparation may further comprise protease inhibitor(s), metal ions, a buffer system, preservative(s), tonicity agent(s), chelating agent(s), stabilizers and surfactants.
In one embodiment the metal ion is zinc, wherein zinc is added as zinc acetate or zinc chloride.
In one embodiment the insulin preparations comprise a human insulin, an analogue or combinations thereof, nicotinamide and/or nicotinic acid and/or salts thereof and arginine and/or salts thereof.
In one embodiment, the insulin preparations according to the present invention comprise an aqueous solution of B28Asp human insulin, nicotinamide and arginine.
The content of B28Asp human insulin in the solutions of this invention may be in the range of 15 to 500 international units (IU)/ml, preferably in the range of 50 to 333 IU/ml, in preparations for injection. However, for other purposes of parenteral administration, the con-tent of insulin compound may be higher.
In the present context the unit "IU" corresponds to 6 nmol.
FIELD OF THE INVENTION
The present invention relates to pharmaceutical preparations comprising an insulin com-BACKGROUND OF THE INVENTION
Diabetes mellitus is a metabolic disorder in which the ability to utilize glucose is partly or completely lost. About 5% of all people suffer from diabetes and the disorder approaches ep-idemic proportions.
Since the introduction of insulin in the 1920's, continuous improvements have been made in the treatment of diabetes. To help avoid high glycaemia levels, diabetic patients of-ten practice multiple injection therapy, whereby insulin is administered with each meal. As diabetic patients have been treated with insulin for several decades, there is a major need for safe and life-quality improving insulin preparations. Among the commercially available insulin In the treatment of diabetes mellitus, many varieties of pharmaceutical preparations of insulin have been suggested and used, such as regular insulin (such as Actrapide), isophane insulin (designated NPH), insulin zinc suspensions (such as Semilente , Lente , and Ul-International applications WO 91/09617 and WO/9610417 (Novo Nordisk NS) disclose insu-lin preparations containing nicotinamide or nicotinic acid or a salt thereof.
European applica-tion EP1283051 allegedly discloses insulin preparation containing arginine, where arginine is used as buffering agent. EP1283051 allegedly discloses improvement of physical stability of Most often pharmaceutical preparations of insulins are administered by subcutane-ous injection. Important for the patient is the action profile of the insulin, meaning the action of insulin on glucose metabolism as a function of time from injection. In this profile, inter alia, the time of the onset, the maximum value and the total duration of action are important. In the case of bolus insulins, a variety of insulin preparations with different action profiles are desired and requested by the patients. One patient may, on the same day, use insulin prepa-rations with very different action profiles. The action profile desired for example, depends on the time of the day and the amount and composition of the meal eaten by the patient.
Equally important for the patient is the chemical stability of the insulin preparations, for example, due to the abundant use of pen-like injection devices such as devices which contain Penfill cartridges, in which an insulin preparation is stored until the entire cartridge is empty which may be at least 1 to 2 weeks for devices containing 1.5-3.0mIcartridges. During storage, covalent chemical changes in the insulin structure occur. This may lead to formation of molecules which may be less active and/or potentially immunogenic such as deamidation products and higher molecular weight transformation products (dimers, polymers). Further-more, also important is the physical stability of the insulin preparations, since long term stor-age may eventually lead to formation of insoluble fibrils, which are biologically inactive and potentially immunogenic.
SUMMARY OF THE INVENTION
The invention relates to insulin preparations with favourable absorption rate and favourable chemical and physical stability. The present invention relates to insulin preparations compris-ing human insulin and/or analogues thereof, nicotinamide or nicotinic acid and/or salts there-of and arginine.
In one embodiment, the present invention relates to an insulin preparation comprising:
= an insulin compound, = a nicotinic compound, and = arginine.
In another embodiment, the present invention also contemplates a method for the treatment of diabetes mellitus in a subject or for reducing the blood glucose level in a subject compris-ing administering to a subject or mammal an insulin preparation according to the invention.
DESCRIPTION OF THE DRAWINGS
Figure 1 shows the development in percentage of total insulin content of degradation prod-ucts during 2 weeks of storage at 37 C of preparations according to the present invention.
The letter A refers to a NovoRapid reference and remaining letters correspond to insulin as-part preparations as described in Table 1 of Example 1. Compared to the NovoRapid prep-aration (preparation A), addition of nicotinamide (preparations B and D) leads to an in-creased formation of degradation products, whereas the combined addition of nicotinamide, glutamic acid and arginine (preparations C and E), has a mostly similar degradation pattern, with lower formation of HMWP.
Figure 2 shows the development in percentage of total insulin content of degradation prod-ucts during 2 weeks of storage at 37 C of preparations according to this invention. The letter A refers to a NovoRapid reference and remaining letters correspond to insulin aspart prepa-rations as described in Table 1 of Example 1. The combined addition of nicotinamide, glu-tamic acid and arginine, preparations F, G, H, and I, differing in buffer system, phosphate or tris buffer, and concentration of insulin and Zn, 0.6mM and 0.3mM or 1.2mM and 0.6mM, has a degradation pattern similar to the NovoRapid preparation, preparation A.
Figure 3 shows the glucose concentration (mean +/- SEM, N=8) in plasma after subcutane-ous injection in pigs of a lnmol/kg dose at 0 minutes of preparations according to this inven-tion. The letter A refers to a NovoRapid reference and remaining letters correspond to insu-lin aspart preparations as described in Table 1 of Example 1. Compared to the NovoRapid preparation (preparation A) the initial rate of plasma glucose lowering is faster for the prepa-ration with addition of nicotinamide (preparation N) and even faster for a combination of nico-tinamide and arginine (preparation M).
Figure 4 shows the glucose concentration in plasma (mean +/- SEM, N=7) after subcutane-ous injection in pigs of a lnmol/kg dose at 0 minutes of preparations according to this inven-tion. The letter A refers to a NovoRapid reference and remaining letters correspond to insu-lin aspart preparations as described in Table 1 of Example 1. Compared to the NovoRapid preparation (preparation A), the initial rate of plasma glucose lowering is faster for a prepara-tion with a combination of nicotinamide, arginine and glutamic acid (preparation L) and for a preparation with a combination of nicotinamide and arginine (preparation K).
Figure 5 shows the insulin aspart concentration in plasma (mean +/- SEM, N=7) after subcu-taneous injection in pigs of a 1 nmol/kg dose at 0 minutes of preparations according to this invention. The letter A refers to a NovoRapid reference and remaining letters correspond to insulin aspart preparations as described in Table 1 of Example 1. Compared to the No-voRapid preparation, (preparation A) , the initial absorption rate of the insulin component of the preparations with nicotinamide (preparation J), the combination of nicotinamide and ar-ginine (preparation K), and the combination of nicotinamide, arginine and glutamic acid (preparation L) is markedly faster.
Figure 6 shows the glucose concentration in plasma (mean +/- SEM, N=8, each pig dosed twice) after subcutaneous injection in pigs of a lnmol/kg dose at 0 minutes of preparations according to this invention. The letter A refers to a NovoRapid reference and number 11 corresponds to a insulin aspart preparation as described in Table 3 of Example 1. Compared to the NovoRapid preparation (preparation A), the initial rate of plasma glucose lowering is faster for a preparation with a combination of nicotinamide and arginine (preparation 11).
Figure 7 shows the insulin aspart concentration in plasma (mean +/- SEM, N=8, each pig dosed twice) after subcutaneous injection in pigs of a 1 nmol/kg dose at 0 minutes of prepa-rations according to this invention. The letter A refers to a NovoRapid reference and number 11 corresponds to a insulin aspart preparation as described in Table 3 of Example 1. Com-pared to the NovoRapid preparation (preparation A), the initial absorption rate of the insulin component of the preparations with nicotinamide and arginine (preparation 11) is markedly faster.
DESCRIPTION OF THE INVENTION
The absorption after subcutaneous injection of the insulin compound in the insulin prepara-tions of the present invention was surprisingly found to be faster than that of the reference insulin preparations. This property is useful for rapid-acting insulins, in particular in connec-tion with a multiple injection regimen where insulin is given before each meal. With faster on-set of action, the insulin can conveniently be taken closer to the meal than with conventional rapid acting insulin solutions. Furthermore, a faster disappearance of insulin probably dimin-ishes the risk of post-meal hypoglycaemia.
The insulin preparations of the present invention are rapid-acting insulin prepara-tions comprising an insulin compound such as insulin aspart, a nicotinic compound, such as nicotinamide and the amino acid arginine. Optionally, the insulin preparations of the present invention may comprise further amino acids. These insulin preparations have a rapid absorp-tion profile that mimics normal physiology more closely than existing therapies. Furthermore, the insulin preparations of the present invention have chemical and physical stability suitable for commercial pharmaceutical preparations.
The insulin preparations of the present invention provide fast-acting insulin prepara-tions which are not only physically stable, but surprisingly also chemically stable. The insulin preparations of the present invention provide an even faster onset of action compared with existing insulin therapies. Such ultra-fast insulin preparations have the advantage of restoring 5 first phase insulin release, injection convenience and shutting down hepatic glucose produc-tion. The insulin preparations of the present invention have a favourable absorption rate from subcutis into plasma with an increase in initial absorption rate ranging from 1.5 to 5 times, when compared to conventional preparations such as NovoRapid , as suggested by several PK/PD experiments in pigs. This faster absorption rate may improve glycaemic control and convenience and may allow for a shift from pre-meal to post-meal dosing. The present inven-tion is based in part, on the surprising discovery that although, the addition of nicotinamide allows the increase in absorption rate, it also has a negative effect on chemical stability by significantly increasing the amount of HMWP. The insulin preparations of the present inven-tion have an improved chemical stability by addition of arginine, which is reflected in e.g. a reduction in the formation of dimers and polymers and desamido insulins after storage. The insulin preparations of the present invention may furthermore also have improved physical stability, which may be useful for use in pumps.
The present invention provides an insulin preparation comprising an insulin com-pound according to the present invention which is present in a concentration from about 0.1 mM to about 10.0mM, and wherein said preparation has a pH from 3 to 8.5. The preparation also comprises a nicotinic compound and arginine. The preparation may further comprise protease inhibitor(s), metal ions, a buffer system, preservative(s), tonicity agent(s), chelating agent(s), stabilizers and surfactants.
In one embodiment the metal ion is zinc, wherein zinc is added as zinc acetate or zinc chloride.
In one embodiment the insulin preparations comprise a human insulin, an analogue or combinations thereof, nicotinamide and/or nicotinic acid and/or salts thereof and arginine and/or salts thereof.
In one embodiment, the insulin preparations according to the present invention comprise an aqueous solution of B28Asp human insulin, nicotinamide and arginine.
The content of B28Asp human insulin in the solutions of this invention may be in the range of 15 to 500 international units (IU)/ml, preferably in the range of 50 to 333 IU/ml, in preparations for injection. However, for other purposes of parenteral administration, the con-tent of insulin compound may be higher.
In the present context the unit "IU" corresponds to 6 nmol.
The term "insulin aspart" refers to the human insulin analogue B28Asp human insu-lin.
The term "onset" refers to the time from injection until the PK curve shifts to an in-crease.
The term "absorption rate" refers to the slope of the PK curve.
An "insulin compound" according to the invention is herein to be understood as hu-man insulin, an insulin analogue and/or any combination thereof.
The term "human insulin" as used herein means the human hormone whose struc-ture and properties are well-known. Human insulin has two polypeptide chains that are con-nected by disulphide bridges between cysteine residues, namely the A-chain and the B-chain. The A-chain is a 21 amino acid peptide and the B-chain is a 30 amino acid peptide, the two chains being connected by three disulphide bridges: one between the cysteines in position 6 and 11 of the A-chain, the second between the cysteine in position 7 of the A-chain and the cysteine in position 7 of the B-chain, and the third between the cysteine in po-sition 20 of the A-chain and the cysteine in position 19 of the B-chain.
The hormone is synthesized as a single-chain precursor proinsulin (preproinsulin) consisting of a prepeptide of 24 amino acids followed by proinsulin containing 86 amino acids in the configuration: prepeptide-B-Arg Arg-C-Lys Arg-A, in which C is a connecting peptide of 31 amino acids. Arg-Arg and Lys-Arg are cleavage sites for cleavage of the connecting pep-tide from the A and B chains.
By "insulin analogue" as used herein is meant a polypeptide derived from the pri-mary structure of a naturally occurring insulin, for example that of human insulin, by mutation.
One or more mutations are made by deleting and/or substituting at least one amino acid res-idue occurring in the naturally occurring insulin and/or by adding at least one amino acid res-idue. The added and/or substituted amino acid residues can either be codable amino acid residues or other naturally occurring amino acid residues.
In one embodiment an insulin analogue comprises less than 8 modifications (substi-tutions, deletions, additions and any combination thereof) relative to the parent insulin, alter-natively less than 7 modifications relative to the parent insulin, alternatively less than 6 mod i-fications relative to the parent insulin, alternatively less than 5 modifications relative to the parent insulin, alternatively less than 4 modifications relative to the parent insulin, alterna-tively less than 3 modifications relative to the parent insulin, alternatively less than 2 modifi-cations relative to the parent insulin.
Mutations in the insulin molecule are denoted stating the chain (A or B), the position, and the three letter code for the amino acid substituting the native amino acid. By "desB30"
or "B(1-29)" is meant a natural insulin B chain or analogue thereof lacking the B30 amino ac-id residue, and by B28Asp human insulin is meant human insulin wherein the amino acid resi-due in position 28 of the B chain has been substituted with Asp.
Examples of insulin analogues are such wherein Pro in position 28 of the B
chain is mutated with Asp, Lys, Leu, Val, or Ala and/or Lys at position B29 is mutated with Pro, Glu or Asp. Furthermore, Asn at position B3 may be mutated with Thr, Lys, Gln, Glu or Asp. The amino acid residue in position A21 may be mutated with Gly. The amino acid in position B1 may be mutated with Glu. The amino acid in position B16 may be mutated with Glu or His.
Further examples of insulin analogues are the deletion analogues e.g.
analogues where the B30 amino acid in human insulin has been deleted (des(B30) human insulin), insulin ana-logues wherein the B1 amino acid in human insulin has been deleted (des(B1) human insu-lin), des(B28-630) human insulin and des(B27) human insulin. Insulin analogues wherein the A-chain and/or the B-chain have an N-terminal extension and insulin analogues wherein the A-chain and/or the B-chain have a C-terminal extension such as with two arginine residues added to the C-terminal of the B-chain are also examples of insulin analogues.
Further ex-amples are insulin analogues comprising combinations of the mentioned mutations. Insulin analogues wherein the amino acid in position A14 is Asn, Gln, Glu, Arg, Asp, Gly or His, the amino acid in position B25 is His and which optionally further comprises one or more addi-tional mutations are further examples of insulin analogues. Insulin analogues of human insu-lin wherein the amino acid residue in position A21 is Gly and wherein the insulin analogue is further extended in the C-terminal with two arginine residues are also examples of insulin analogues.
Further examples of insulin analogues include, but are not limited to: DesB30 human insulin; AspB28 human insulin; AspB28,desB30 human insulin; LysB3,GluB29 human insulin;
LysB28,ProB29 human insulin; GlyA21,ArgB31,ArgB32 human insulin; GluA14,HisB25 hu-man insulin; HisA14,HisB25 human insulin; GluA14,HisB25,desB30 human insulin;
HisA14, HisB25,desB30 human insulin; GluA14,HisB25,desB27,desB28,desB29,desB30 human insu-lin; GluA14,HisB25,GluB27,desB30 human insulin; GluA14,HisB16,HisB25,desB30 human insulin; HisA14,HisB16,HisB25,desB30 human insulin;
HisA8,GluA14,HisB25,GluB27,desB30 human insulin;
HisA8,GluA14,GluB1,GluB16,HisB25,GluB27,desB30 human insulin; and HisA8,GluA14,GluB16,HisB25,desB30 human insulin.
The term "nicotinic compound" includes nicotinamide, nicotinic acid, niacin, niacin amide and vitamin B3 and/or salts thereof and/or any combination thereof.
The term "onset" refers to the time from injection until the PK curve shifts to an in-crease.
The term "absorption rate" refers to the slope of the PK curve.
An "insulin compound" according to the invention is herein to be understood as hu-man insulin, an insulin analogue and/or any combination thereof.
The term "human insulin" as used herein means the human hormone whose struc-ture and properties are well-known. Human insulin has two polypeptide chains that are con-nected by disulphide bridges between cysteine residues, namely the A-chain and the B-chain. The A-chain is a 21 amino acid peptide and the B-chain is a 30 amino acid peptide, the two chains being connected by three disulphide bridges: one between the cysteines in position 6 and 11 of the A-chain, the second between the cysteine in position 7 of the A-chain and the cysteine in position 7 of the B-chain, and the third between the cysteine in po-sition 20 of the A-chain and the cysteine in position 19 of the B-chain.
The hormone is synthesized as a single-chain precursor proinsulin (preproinsulin) consisting of a prepeptide of 24 amino acids followed by proinsulin containing 86 amino acids in the configuration: prepeptide-B-Arg Arg-C-Lys Arg-A, in which C is a connecting peptide of 31 amino acids. Arg-Arg and Lys-Arg are cleavage sites for cleavage of the connecting pep-tide from the A and B chains.
By "insulin analogue" as used herein is meant a polypeptide derived from the pri-mary structure of a naturally occurring insulin, for example that of human insulin, by mutation.
One or more mutations are made by deleting and/or substituting at least one amino acid res-idue occurring in the naturally occurring insulin and/or by adding at least one amino acid res-idue. The added and/or substituted amino acid residues can either be codable amino acid residues or other naturally occurring amino acid residues.
In one embodiment an insulin analogue comprises less than 8 modifications (substi-tutions, deletions, additions and any combination thereof) relative to the parent insulin, alter-natively less than 7 modifications relative to the parent insulin, alternatively less than 6 mod i-fications relative to the parent insulin, alternatively less than 5 modifications relative to the parent insulin, alternatively less than 4 modifications relative to the parent insulin, alterna-tively less than 3 modifications relative to the parent insulin, alternatively less than 2 modifi-cations relative to the parent insulin.
Mutations in the insulin molecule are denoted stating the chain (A or B), the position, and the three letter code for the amino acid substituting the native amino acid. By "desB30"
or "B(1-29)" is meant a natural insulin B chain or analogue thereof lacking the B30 amino ac-id residue, and by B28Asp human insulin is meant human insulin wherein the amino acid resi-due in position 28 of the B chain has been substituted with Asp.
Examples of insulin analogues are such wherein Pro in position 28 of the B
chain is mutated with Asp, Lys, Leu, Val, or Ala and/or Lys at position B29 is mutated with Pro, Glu or Asp. Furthermore, Asn at position B3 may be mutated with Thr, Lys, Gln, Glu or Asp. The amino acid residue in position A21 may be mutated with Gly. The amino acid in position B1 may be mutated with Glu. The amino acid in position B16 may be mutated with Glu or His.
Further examples of insulin analogues are the deletion analogues e.g.
analogues where the B30 amino acid in human insulin has been deleted (des(B30) human insulin), insulin ana-logues wherein the B1 amino acid in human insulin has been deleted (des(B1) human insu-lin), des(B28-630) human insulin and des(B27) human insulin. Insulin analogues wherein the A-chain and/or the B-chain have an N-terminal extension and insulin analogues wherein the A-chain and/or the B-chain have a C-terminal extension such as with two arginine residues added to the C-terminal of the B-chain are also examples of insulin analogues.
Further ex-amples are insulin analogues comprising combinations of the mentioned mutations. Insulin analogues wherein the amino acid in position A14 is Asn, Gln, Glu, Arg, Asp, Gly or His, the amino acid in position B25 is His and which optionally further comprises one or more addi-tional mutations are further examples of insulin analogues. Insulin analogues of human insu-lin wherein the amino acid residue in position A21 is Gly and wherein the insulin analogue is further extended in the C-terminal with two arginine residues are also examples of insulin analogues.
Further examples of insulin analogues include, but are not limited to: DesB30 human insulin; AspB28 human insulin; AspB28,desB30 human insulin; LysB3,GluB29 human insulin;
LysB28,ProB29 human insulin; GlyA21,ArgB31,ArgB32 human insulin; GluA14,HisB25 hu-man insulin; HisA14,HisB25 human insulin; GluA14,HisB25,desB30 human insulin;
HisA14, HisB25,desB30 human insulin; GluA14,HisB25,desB27,desB28,desB29,desB30 human insu-lin; GluA14,HisB25,GluB27,desB30 human insulin; GluA14,HisB16,HisB25,desB30 human insulin; HisA14,HisB16,HisB25,desB30 human insulin;
HisA8,GluA14,HisB25,GluB27,desB30 human insulin;
HisA8,GluA14,GluB1,GluB16,HisB25,GluB27,desB30 human insulin; and HisA8,GluA14,GluB16,HisB25,desB30 human insulin.
The term "nicotinic compound" includes nicotinamide, nicotinic acid, niacin, niacin amide and vitamin B3 and/or salts thereof and/or any combination thereof.
According to the present invention, the concentration of the nicotinic compound and/or salts thereof is in the range from about 1mM to about 300mM or from about 5mM to about 200mM.
The term "arginine" or "Arg" includes the amino acid arginine and/or a salt thereof, e.g. arginine hydrochloride or arginine glutamate.
In one embodiment, the insulin preparation comprises 1 to 100mM of arginine.
In one embodiment, the insulin preparation comprises 1 to 20mM of arginine.
In one embodiment, the insulin preparation comprises 20 to 90mM of arginine.
In one embodiment, the insulin preparation comprises 30 to 85mM of arginine.
The term "glutamic acid" or "Glu" includes the aminoacid glutamic acid and/or a salt thereof.
The term "pharmaceutical preparation" or "insulin preparation" as used herein means a product comprising an insulin compound, i.e., a human insulin, an analogue thereof and/or combinations thereof and a nicotinic compound and an aminoacid, optionally together with other excipients such as preservatives, chelating agents, tonicity modifiers, bulking agents, stabilizers, antioxidants, polymers and surfactants, metal ions, oleaginous vehicles and proteins (e.g., human serum albumin, gelatine or proteins), said insulin preparation being useful for treating, preventing or reducing the severity of a disease or disorder by administration of said insulin preparation to a person. Thus, an insulin preparation is also known in the art as a pharmaceutical preparation or pharmaceutical composition.
The buffer may be selected from the group consisting of, but not limited to, sodium acetate, sodium carbonate, citrate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethan (tris), bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid, ethylendiamine or mixtures thereof. Each one of these specific buffers constitutes an alternative embodiment of the invention.
The insulin preparation of the present invention may further comprise other ingredi-ents common to insulin preparations, for example zinc complexing agents such as citrate, and phosphate buffers.
Glycerol and/or mannitol and/or sodium chloride may be present in an amount cor-responding to a concentration of 0 to 250mM, 0 to 200mM or 0 to 100mM.
Stabilizers, surfactants and preservatives may also be present in the insulin preparations of this invention.
The term "arginine" or "Arg" includes the amino acid arginine and/or a salt thereof, e.g. arginine hydrochloride or arginine glutamate.
In one embodiment, the insulin preparation comprises 1 to 100mM of arginine.
In one embodiment, the insulin preparation comprises 1 to 20mM of arginine.
In one embodiment, the insulin preparation comprises 20 to 90mM of arginine.
In one embodiment, the insulin preparation comprises 30 to 85mM of arginine.
The term "glutamic acid" or "Glu" includes the aminoacid glutamic acid and/or a salt thereof.
The term "pharmaceutical preparation" or "insulin preparation" as used herein means a product comprising an insulin compound, i.e., a human insulin, an analogue thereof and/or combinations thereof and a nicotinic compound and an aminoacid, optionally together with other excipients such as preservatives, chelating agents, tonicity modifiers, bulking agents, stabilizers, antioxidants, polymers and surfactants, metal ions, oleaginous vehicles and proteins (e.g., human serum albumin, gelatine or proteins), said insulin preparation being useful for treating, preventing or reducing the severity of a disease or disorder by administration of said insulin preparation to a person. Thus, an insulin preparation is also known in the art as a pharmaceutical preparation or pharmaceutical composition.
The buffer may be selected from the group consisting of, but not limited to, sodium acetate, sodium carbonate, citrate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethan (tris), bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid, ethylendiamine or mixtures thereof. Each one of these specific buffers constitutes an alternative embodiment of the invention.
The insulin preparation of the present invention may further comprise other ingredi-ents common to insulin preparations, for example zinc complexing agents such as citrate, and phosphate buffers.
Glycerol and/or mannitol and/or sodium chloride may be present in an amount cor-responding to a concentration of 0 to 250mM, 0 to 200mM or 0 to 100mM.
Stabilizers, surfactants and preservatives may also be present in the insulin preparations of this invention.
The insulin preparations of the present invention may further comprise a pharmaceutically acceptable preservative. The preservative may be present in an amount sufficient to obtain a preserving effect. The amount of preservative in an insulin preparation may be determined from e.g. literature in the field and/or the known amount(s) of preservative in e.g. commercial products. Each one of these specific preservatives constitutes an alternative embodiment of the invention. The use of a preservative in pharmaceutical preparations is described, for example in Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
The preservative present in the insulin preparation of this invention may be as in the heretofore conventional insulin preparations, for example phenol, m-cresol and methylpara-ben.
The insulin preparation of the present invention may further comprise a chelating agent. The use of a chelating agent in pharmaceutical preparations is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
The insulin preparation of the present invention may further comprise a stabilizer.
The term "stabilizer" as used herein refers to chemicals added to polypeptide containing pharmaceutical preparations in order to stabilize the peptide, i.e. to increase the shelf life and/or in-use time of such preparations. For convenience reference is made to Remington:
The Science and Practice of Pharmacy, 19th edition, 1995.
The insulin preparation of the present invention may further comprise a surfactant.
The term "surfactant" as used herein refers to any molecules or ions that are comprised of a water-soluble (hydrophilic) part, the head, and a fat-soluble (lipophilic) segment. Surfactants accumulate preferably at interfaces, which the hydrophilic part is orientated towards the wa-ter (hydrophilic phase) and the lipophilic part towards the oil- or hydrophobic phase (i.e.
glass, air, oil etc.). The concentration at which surfactants begin to form micelles is known as the critical micelle concentration or CMC. Furthermore, surfactants lower the surface tension of a liquid. Surfactants are also known as amphipathic compounds. The term "detergent" is a synonym used for surfactants in general. The use of a surfactant in pharmaceutical prepare-tions is well-known to the skilled person. For convenience reference is made to Remington:
The Science and Practice of Pharmacy, 19th edition, 1995.
In a further embodiment the invention relates to an insulin preparation comprising an aqueous solution of an insulin compound of the present invention, and a buffer, wherein said insulin compound is present in a concentration from 0.1mM or above, and wherein said preparation has a pH from about 3.0 to about 8.5 at room temperature (-25 C).
The present invention also relates to methods for producing the insulin preparations of the invention.
In one embodiment, the method for making insulin preparations of the invention comprises:
5 a) preparing a solution by dissolving the insulin compound or a mixture of insulin compounds in water or buffer;
b) preparing a solution by dissolving a divalent metal ion in water or buffer;
c) preparing a solution by dissolving a preservative in water or buffer;
d) preparing a solution by dissolving a tonicity agent in water or buffer;
The preservative present in the insulin preparation of this invention may be as in the heretofore conventional insulin preparations, for example phenol, m-cresol and methylpara-ben.
The insulin preparation of the present invention may further comprise a chelating agent. The use of a chelating agent in pharmaceutical preparations is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
The insulin preparation of the present invention may further comprise a stabilizer.
The term "stabilizer" as used herein refers to chemicals added to polypeptide containing pharmaceutical preparations in order to stabilize the peptide, i.e. to increase the shelf life and/or in-use time of such preparations. For convenience reference is made to Remington:
The Science and Practice of Pharmacy, 19th edition, 1995.
The insulin preparation of the present invention may further comprise a surfactant.
The term "surfactant" as used herein refers to any molecules or ions that are comprised of a water-soluble (hydrophilic) part, the head, and a fat-soluble (lipophilic) segment. Surfactants accumulate preferably at interfaces, which the hydrophilic part is orientated towards the wa-ter (hydrophilic phase) and the lipophilic part towards the oil- or hydrophobic phase (i.e.
glass, air, oil etc.). The concentration at which surfactants begin to form micelles is known as the critical micelle concentration or CMC. Furthermore, surfactants lower the surface tension of a liquid. Surfactants are also known as amphipathic compounds. The term "detergent" is a synonym used for surfactants in general. The use of a surfactant in pharmaceutical prepare-tions is well-known to the skilled person. For convenience reference is made to Remington:
The Science and Practice of Pharmacy, 19th edition, 1995.
In a further embodiment the invention relates to an insulin preparation comprising an aqueous solution of an insulin compound of the present invention, and a buffer, wherein said insulin compound is present in a concentration from 0.1mM or above, and wherein said preparation has a pH from about 3.0 to about 8.5 at room temperature (-25 C).
The present invention also relates to methods for producing the insulin preparations of the invention.
In one embodiment, the method for making insulin preparations of the invention comprises:
5 a) preparing a solution by dissolving the insulin compound or a mixture of insulin compounds in water or buffer;
b) preparing a solution by dissolving a divalent metal ion in water or buffer;
c) preparing a solution by dissolving a preservative in water or buffer;
d) preparing a solution by dissolving a tonicity agent in water or buffer;
10 e) preparing a solution by dissolving a surfactant and/or a stabilizer in water or buff-er;
f) mixing solution a) and one or more of solutions b), c), d), and e);
Finally adjusting the pH of the mixture in f) to the desired pH followed by a sterile fil-tration.
In one embodiment, the method for making insulin preparations of the invention comprises:
a) preparing separate stock solutions of preservative agents, tonicity agent, metal ion salt, arginine or arginine salt and nicotinic compound;
b) preparing a solution by adding stock solution(s) of preservative or a mixture of preservatives to water or buffer;
c) adding stock solution of tonicity agent to solution b);
d) preparing a solution by dissolving the insulin compound or a mixture of insulin compounds in water or buffer; adding HCI to acidify this solution;
e) adding stock solution of metal ion salt to d);
f) adding e) to c) and stirring;
g) adding stock solution of arginine or arginine salt to f) and stirring;
h) adding stock solution of nicotinic compound to g) and adjusting pH with Na0H/HCI to desired pH.
In one embodiment, the method for making insulin preparations of the invention comprises:
a) preparing separate stock solutions of preservative agents, tonicity agent, metal ion salt, and a mixed stock solution of Arginine or Arginine salt and nicotinic compound b) preparing a solution by adding stock solution(s) of preservative or a mixture of preservatives to water or buffer;
c) adding stock solution of tonicity agent to solution b);
d) preparing a solution by dissolving the insulin compound or a mixture of insulin compounds in water or buffer; adding HCI to acidify this solution;
e) adding stock solution of metal ion salt to d);
f) adding e) to c) and stirring;
g) adding mixed stock solution of Arginine or Arginine salt and nicotinic compound to f) and stirring;
h) adjusting pH of g) with Na0H/HCI to desired pH.
The insulin preparations of the present invention can be used in the treatment of di-abetes by parenteral administration. It is recommended that the dosage of the insulin prepa-rations of this invention which is to be administered to the patient be selected by a physician.
Parenteral administration may be performed by subcutaneous, intramuscular, in-traperitoneal or intravenous injection by means of a syringe, optionally a pen-like syringe.
Alternatively, parenteral administration can be performed by means of an infusion pump. As a further option, the insulin preparations containing the insulin compound of the invention can also be adapted to transdermal administration, e.g. by needle-free injection or from a patch, optionally an iontophoretic patch, or transmucosal, e.g. buccal, administration.
Insulin preparations according to the present invention may be administered to a pa-tient in need of such treatment at several sites, for example, at topical sites, for example, skin and mucosal sites, at sites which bypass absorption, for example, administration in an artery, in a vein, in the heart, and at sites which involve absorption, for example, administration in the skin, under the skin, in a muscle or in the abdomen.
In one embodiment of the invention the insulin preparation is an aqueous prepara-tion, i.e. preparation comprising water. Such preparation is typically a solution or a suspen-sion. In a further embodiment of the invention the insulin preparation is an aqueous solution.
The term "aqueous preparation" is defined as a preparation comprising at least %w/w water. Likewise, the term "aqueous solution" is defined as a solution comprising at least 50 %w/w water, and the term "aqueous suspension" is defined as a suspension com-prising at least 50 %w/w water.
Aqueous suspensions may contain the active compounds in admixture with excipients suitable for the manufacture of aqueous suspensions.
f) mixing solution a) and one or more of solutions b), c), d), and e);
Finally adjusting the pH of the mixture in f) to the desired pH followed by a sterile fil-tration.
In one embodiment, the method for making insulin preparations of the invention comprises:
a) preparing separate stock solutions of preservative agents, tonicity agent, metal ion salt, arginine or arginine salt and nicotinic compound;
b) preparing a solution by adding stock solution(s) of preservative or a mixture of preservatives to water or buffer;
c) adding stock solution of tonicity agent to solution b);
d) preparing a solution by dissolving the insulin compound or a mixture of insulin compounds in water or buffer; adding HCI to acidify this solution;
e) adding stock solution of metal ion salt to d);
f) adding e) to c) and stirring;
g) adding stock solution of arginine or arginine salt to f) and stirring;
h) adding stock solution of nicotinic compound to g) and adjusting pH with Na0H/HCI to desired pH.
In one embodiment, the method for making insulin preparations of the invention comprises:
a) preparing separate stock solutions of preservative agents, tonicity agent, metal ion salt, and a mixed stock solution of Arginine or Arginine salt and nicotinic compound b) preparing a solution by adding stock solution(s) of preservative or a mixture of preservatives to water or buffer;
c) adding stock solution of tonicity agent to solution b);
d) preparing a solution by dissolving the insulin compound or a mixture of insulin compounds in water or buffer; adding HCI to acidify this solution;
e) adding stock solution of metal ion salt to d);
f) adding e) to c) and stirring;
g) adding mixed stock solution of Arginine or Arginine salt and nicotinic compound to f) and stirring;
h) adjusting pH of g) with Na0H/HCI to desired pH.
The insulin preparations of the present invention can be used in the treatment of di-abetes by parenteral administration. It is recommended that the dosage of the insulin prepa-rations of this invention which is to be administered to the patient be selected by a physician.
Parenteral administration may be performed by subcutaneous, intramuscular, in-traperitoneal or intravenous injection by means of a syringe, optionally a pen-like syringe.
Alternatively, parenteral administration can be performed by means of an infusion pump. As a further option, the insulin preparations containing the insulin compound of the invention can also be adapted to transdermal administration, e.g. by needle-free injection or from a patch, optionally an iontophoretic patch, or transmucosal, e.g. buccal, administration.
Insulin preparations according to the present invention may be administered to a pa-tient in need of such treatment at several sites, for example, at topical sites, for example, skin and mucosal sites, at sites which bypass absorption, for example, administration in an artery, in a vein, in the heart, and at sites which involve absorption, for example, administration in the skin, under the skin, in a muscle or in the abdomen.
In one embodiment of the invention the insulin preparation is an aqueous prepara-tion, i.e. preparation comprising water. Such preparation is typically a solution or a suspen-sion. In a further embodiment of the invention the insulin preparation is an aqueous solution.
The term "aqueous preparation" is defined as a preparation comprising at least %w/w water. Likewise, the term "aqueous solution" is defined as a solution comprising at least 50 %w/w water, and the term "aqueous suspension" is defined as a suspension com-prising at least 50 %w/w water.
Aqueous suspensions may contain the active compounds in admixture with excipients suitable for the manufacture of aqueous suspensions.
In one embodiment, the insulin preparations of this invention are well-suited for ap-plication in pen-like devices used for insulin therapy by injection.
In one embodiment the insulin preparations of the present invention can be used in pumps for insulin administration.
The term "physical stability" of the insulin preparation as used herein refers to the tendency of the protein to form biologically inactive and/or insoluble aggregates of the protein as a result of exposure of the protein to thermo-mechanical stresses and/or interaction with interfaces and surfaces that are destabilizing, such as hydrophobic surfaces and interfaces.
Physical stability of the aqueous protein preparations is evaluated by means of visual inspec-tion and/or turbidity measurements after exposing the preparation filled in suitable containers (e.g. cartridges or vials) to mechanical/physical stress (e.g. agitation) at different tempera-tures for various time periods. Visual inspection of the preparations is performed in a sharp focused light with a dark background. The turbidity of the preparation is characterized by a visual score ranking the degree of turbidity for instance on a scale from 0 to 3 (a preparation showing no turbidity corresponds to a visual score 0, and a preparation showing visual tur-bidity in daylight corresponds to visual score 3). A preparation is classified physically unsta-ble with respect to protein aggregation, when it shows visual turbidity in daylight. Alterna-tively, the turbidity of the preparation can be evaluated by simple turbidity measurements well-known to the skilled person. Physical stability of the aqueous protein preparations can also be evaluated by using a spectroscopic agent or probe of the conformational status of the protein. The probe is preferably a small molecule that preferentially binds to a non-native conformer of the protein. One example of a small molecular spectroscopic probe of protein structure is Thioflavin T. Thioflavin T is a fluorescent dye that has been widely used for the detection of amyloid fibrils. In the presence of fibrils, and perhaps other protein configurations as well, Thioflavin T gives rise to a new excitation maximum at about 450 nm and enhanced emission at about 482 nm when bound to a fibril protein form. Unbound Thioflavin T is essen-tially non-fluorescent at the wavelengths.
The term "chemical stability" of the protein preparation as used herein refers to changes in the covalent protein structure leading to formation of chemical degradation prod-ucts with potential less biological potency and/or potential increased immunogenic properties compared to the native protein structure. Various chemical degradation products can be formed depending on the type and nature of the native protein and the environment to which the protein is exposed. Increasing amounts of chemical degradation products is often seen during storage and use of the protein preparation. Most proteins are prone to deamidation, a process in which the side chain amide group in glutaminyl or asparaginyl residues is hydro-lysed to form a free carboxylic acid or asparaginyl residues to form an !soAsp derivative.
Other degradations pathways involves formation of high molecular weight products where two or more protein molecules are covalently bound to each other through transamidation and/or disulfide interactions leading to formation of covalently bound dimer, oligomer and polymer degradation products (Stability of Protein Pharmaceuticals, Ahern.
T.J. & Manning M.C., Plenum Press, New York 1992). Oxidation (of for instance methionine residues) can be mentioned as another variant of chemical degradation. The chemical stability of the protein preparation can be evaluated by measuring the amount of the chemical degradation products at various time-points after exposure to different environmental conditions (the formation of degradation products can often be accelerated by for instance increasing temperature). The amount of each individual degradation product is often determined by separation of the deg-radation products depending on molecule size and/or charge using various chromatography techniques (e.g. SEC-HPLC and/or RP-HPLC). Since HMWP products are potentially immu-nogenic and not biologically active, low levels of HMWP are advantageous.
The term "stabilized preparation" refers to a preparation with increased physical sta-bility, increased chemical stability or increased physical and chemical stability. In general, a preparation must be stable during use and storage (in compliance with recommended use and storage conditions) until the expiration date is reached.
The term "diabetes" or "diabetes mellitus" includes type 1 diabetes, type 2 diabetes, gestational diabetes (during pregnancy) and other states that cause hyperglycaemia. The term is used for a metabolic disorder in which the pancreas produces insufficient amounts of insulin, or in which the cells of the body fail to respond appropriately to insulin thus prevent-ing cells from absorbing glucose. As a result, glucose builds up in the blood.
Type 1 diabetes, also called insulin-dependent diabetes mellitus (IDDM) and juvenile-onset diabetes, is caused by B-cell destruction, usually leading to absolute insulin deficiency.
Type 2 diabetes, also known as non-insulin-dependent diabetes mellitus (NIDDM) and adult-onset diabetes, is associated with predominant insulin resistance and thus relative insulin deficiency and/or a predominantly insulin secretory defect with insulin resistance.
The term "pharmaceutically acceptable" as used herein means suited for normal pharmaceutical applications, i.e., not giving rise to any serious adverse events in patients.
The term "treatment of a disease" as used herein means the management and care of a patient having developed the disease, condition or disorder and includes treatment, pre-vention or alleviation of the disease. The purpose of treatment is to combat the disease, con-dition or disorder. Treatment includes the administration of the active compounds to eliminate or control the disease, condition or disorder as well as to alleviate the symptoms or complica-tions associated with the disease, condition or disorder, and prevention of the disease, condi-tion or disorder.
In its broadest sense, the term a "critically ill patient", as used herein refers to a pa-tient who has sustained or are at risk of sustaining acutely life-threatening single or multiple organ system failure due to disease or injury, a patient who is being operated and where complications supervene, and a patient who has been operated in a vital organ within the last week or has been subject to major surgery within the last week. In a more restricted sense, the term a "critically ill patient", as used herein refers to a patient who has sustained or are at risk of sustaining acutely life-threatening single or multiple organ system failure due to dis-ease or injury, or a patient who is being operated and where complications supervene. In an even more restricted sense, the term a "critically ill patient", as used herein refers to a patient who has sustained or are at risk of sustaining acutely life-threatening single or multiple organ system failure due to disease or injury. Similarly, these definitions apply to similar expres-sions such as "critical illness in a patient" and a "patient is critically ill". Examples of a criti-cally ill patient is a patient in need of cardiac surgery, cerebral surgery, thoracic surgery, ab-dominal surgery, vascular surgery, or transplantation, or a patient suffering from neurological diseases, cerebral trauma, respiratory insufficiency, abdominal peritonitis, multiple trauma or severe burns, or critical illness polyneuropathy.
The term "anabolism" as used herein, means the set of metabolic pathways that construct molecules from smaller units. These reactions require energy. One way of categorizing metabolic processes, whether at the cellular, organ or organism level is as 'anabolic' or as 'catabolic', which is the opposite. Anabolism is powered by catabolism, where large molecules are broken down into smaller parts and then used up in respiration. Many anabolic processes are powered by adenosine triphosphate (ATP). Anabolic processes tend toward "building up" organs and tissues. These processes produce growth and differentiation of cells and increase in body size, a process that involves synthesis of complex molecules.
Examples of anabolic processes include the growth and mineralization of bone and increases in muscle mass. Endocrinologists have traditionally classified hormones as anabolic or catabolic, depending on which part of metabolism they stimulate.
The balance between anabolism and catabolism is also regulated by circadian rhythms, with processes such as glucose metabolism fluctuating to match an animal's normal periods of activity throughout the day. Some examples of the "anabolic effects" of these hormones are increased protein synthesis from amino acids, increased appetite, increased bone remodeling and growth, and stimulation of bone marrow, which increases the production of red blood cells. Through a number of mechanisms anabolic hormones stimulate the formation of muscle cells and hence cause an increase in the size of skeletal muscles, leading to increased strength.
In another embodiment, an insulin analogue according to the invention is used as a medicament for delaying or preventing disease progression in type 2 diabetes.
5 In one embodiment of the present invention, the insulin preparation according to the invention is for use as a medicament for the treatment or prevention of hyperglycemia includ-ing stress induced hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabe-tes, and burns, operation wounds and other diseases or injuries where an anabolic effect is needed in the treatment, myocardial infarction, stroke, coronary heart disease and other car-10 diovascular disorders is provided.
In a further embodiment of the present invention, a method for the treatment or pre-vention of hyperglycemia including stress induced hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, and burns, operation wounds and other diseases or inju-ries where an anabolic effect is needed in the treatment, myocardial infarction, coronary 15 heart disease and other cardiovascular disorders, stroke, the method comprising administer-ing to a patient in need of such treatment an effective amount for such treatment of an insulin preparation according to the invention, is provided.
The treatment with an insulin preparation according to the present invention may also be combined with a second or more pharmacologically active substances, e.g. selected from antidiabetic agents, antiobesity agents, appetite regulating agents, antihypertensive agents, agents for the treatment and/or prevention of complications resulting from or associ-ated with diabetes and agents for the treatment and/or prevention of complications and dis-orders resulting from or associated with obesity.
The treatment with an insulin preparation according to the present invention may also be combined with bariatric surgery - a surgery that influences the glucose levels and/or lipid homeostasis such as gastric banding or gastric bypass.
The production of polypeptides, e.g., insulins, is well known in the art. An insulin analogue according to the invention may for instance be produced by classical peptide syn-thesis, e.g. solid phase peptide synthesis using t-Boc or Fmoc chemistry or other well estab-lished techniques, see e.g. Greene and Wuts, "Protective Groups in Organic Synthesis", John Wiley & Sons, 1999. The insulin analogue may also be produced by a method which comprises culturing a host cell containing a DNA sequence encoding the analogue and ca-pable of expressing the insulin analogue in a suitable nutrient medium under conditions per-mitting the expression of the insulin analogue. For insulin analogues comprising non-natural amino acid residues, the recombinant cell should be modified such that the non-natural amino acids are incorporated into the analogue, for instance by use of tRNA
mutants. Hence, briefly, the insulin analogues according to the invention are prepared analogously to the preparation of known insulin analogues.
Several methods may be used for the production of human insulin and human insu-lin analogues. For example three major methods which are used in the production of insulin in microorganisms are disclosed in W02008034881. Two of these involve Escherichia coli, with either the expression of a large fusion protein in the cytoplasm (Frank et al. (1981) in Peptides: Proceedings of the 7th American Peptide Chemistry Symposium (Rich &
Gross, eds.), Pierce Chemical Co., Rockford, III. pp 729-739), or use of a signal peptide to enable secretion into the periplasmic space (Chan et al. (1981) PNAS 78:5401-5404). A
third meth-od utilizes Saccharomyces cerevisiae to secrete an insulin precursor into the medium (Thim et al. (1986) PNAS 83:6766-6770). The prior art discloses a number of insulin precursors which are expressed in either E. coli or Saccharomyces cerevisiae, vide U.55,962,267, WO
95/16708, EP 0055945, EP 0163529, EP 0347845 and EP 0741188.
The insulin analogues are produced by expressing a DNA sequence encoding the insulin analogue in question in a suitable host cell by well known technique as disclosed in e.g. US 6500645. The insulin analogue is either expressed directly or as a precursor mole-cule which has an N-terminal extension on the B-chain or a C-terminal extension on the B-chain. The N-terminal extension may have the function of increasing the yield of the directly expressed product and may be of up to 15 amino acid residues long. The N-terminal exten-sion is to be cleaved of in vitro after isolation from the culture broth and will therefore have a cleavage site next to B1. N-terminal extensions of the type suitable in the present invention are disclosed in US 5,395,922, and EP 765,395. The C-terminal extension may have the function of protecting the mature insulin or insulin analogue molecule against intracellular proteolytic processing by host cell exoproteases. The C-terminal extension is to be cleaved of either extra-cellularly in the culture broth by secreted, active carboxypeptidase or in vitro after isolation from the culture broth. A method for producing mature insulin and insulin ana-logs with C-terminal extensions on the B-chain that are removed by carboxypetidase are dis-closed in WO 08037735. The target insulin product of the process may either be a two-chain human insulin or a two-chain human insulin analogue which may or may not have a short C-terminal extension of the B-chain. If the target insulin product will have no C-terminal exten-sion of the B-chain, then said C-terminal extension should be capable of subsequently being cleaved off from the B-chain before further purification steps.
The present invention also contemplates the following non-limiting list of embodi-ments, which are further described elsewhere herein:
In one embodiment the insulin preparations of the present invention can be used in pumps for insulin administration.
The term "physical stability" of the insulin preparation as used herein refers to the tendency of the protein to form biologically inactive and/or insoluble aggregates of the protein as a result of exposure of the protein to thermo-mechanical stresses and/or interaction with interfaces and surfaces that are destabilizing, such as hydrophobic surfaces and interfaces.
Physical stability of the aqueous protein preparations is evaluated by means of visual inspec-tion and/or turbidity measurements after exposing the preparation filled in suitable containers (e.g. cartridges or vials) to mechanical/physical stress (e.g. agitation) at different tempera-tures for various time periods. Visual inspection of the preparations is performed in a sharp focused light with a dark background. The turbidity of the preparation is characterized by a visual score ranking the degree of turbidity for instance on a scale from 0 to 3 (a preparation showing no turbidity corresponds to a visual score 0, and a preparation showing visual tur-bidity in daylight corresponds to visual score 3). A preparation is classified physically unsta-ble with respect to protein aggregation, when it shows visual turbidity in daylight. Alterna-tively, the turbidity of the preparation can be evaluated by simple turbidity measurements well-known to the skilled person. Physical stability of the aqueous protein preparations can also be evaluated by using a spectroscopic agent or probe of the conformational status of the protein. The probe is preferably a small molecule that preferentially binds to a non-native conformer of the protein. One example of a small molecular spectroscopic probe of protein structure is Thioflavin T. Thioflavin T is a fluorescent dye that has been widely used for the detection of amyloid fibrils. In the presence of fibrils, and perhaps other protein configurations as well, Thioflavin T gives rise to a new excitation maximum at about 450 nm and enhanced emission at about 482 nm when bound to a fibril protein form. Unbound Thioflavin T is essen-tially non-fluorescent at the wavelengths.
The term "chemical stability" of the protein preparation as used herein refers to changes in the covalent protein structure leading to formation of chemical degradation prod-ucts with potential less biological potency and/or potential increased immunogenic properties compared to the native protein structure. Various chemical degradation products can be formed depending on the type and nature of the native protein and the environment to which the protein is exposed. Increasing amounts of chemical degradation products is often seen during storage and use of the protein preparation. Most proteins are prone to deamidation, a process in which the side chain amide group in glutaminyl or asparaginyl residues is hydro-lysed to form a free carboxylic acid or asparaginyl residues to form an !soAsp derivative.
Other degradations pathways involves formation of high molecular weight products where two or more protein molecules are covalently bound to each other through transamidation and/or disulfide interactions leading to formation of covalently bound dimer, oligomer and polymer degradation products (Stability of Protein Pharmaceuticals, Ahern.
T.J. & Manning M.C., Plenum Press, New York 1992). Oxidation (of for instance methionine residues) can be mentioned as another variant of chemical degradation. The chemical stability of the protein preparation can be evaluated by measuring the amount of the chemical degradation products at various time-points after exposure to different environmental conditions (the formation of degradation products can often be accelerated by for instance increasing temperature). The amount of each individual degradation product is often determined by separation of the deg-radation products depending on molecule size and/or charge using various chromatography techniques (e.g. SEC-HPLC and/or RP-HPLC). Since HMWP products are potentially immu-nogenic and not biologically active, low levels of HMWP are advantageous.
The term "stabilized preparation" refers to a preparation with increased physical sta-bility, increased chemical stability or increased physical and chemical stability. In general, a preparation must be stable during use and storage (in compliance with recommended use and storage conditions) until the expiration date is reached.
The term "diabetes" or "diabetes mellitus" includes type 1 diabetes, type 2 diabetes, gestational diabetes (during pregnancy) and other states that cause hyperglycaemia. The term is used for a metabolic disorder in which the pancreas produces insufficient amounts of insulin, or in which the cells of the body fail to respond appropriately to insulin thus prevent-ing cells from absorbing glucose. As a result, glucose builds up in the blood.
Type 1 diabetes, also called insulin-dependent diabetes mellitus (IDDM) and juvenile-onset diabetes, is caused by B-cell destruction, usually leading to absolute insulin deficiency.
Type 2 diabetes, also known as non-insulin-dependent diabetes mellitus (NIDDM) and adult-onset diabetes, is associated with predominant insulin resistance and thus relative insulin deficiency and/or a predominantly insulin secretory defect with insulin resistance.
The term "pharmaceutically acceptable" as used herein means suited for normal pharmaceutical applications, i.e., not giving rise to any serious adverse events in patients.
The term "treatment of a disease" as used herein means the management and care of a patient having developed the disease, condition or disorder and includes treatment, pre-vention or alleviation of the disease. The purpose of treatment is to combat the disease, con-dition or disorder. Treatment includes the administration of the active compounds to eliminate or control the disease, condition or disorder as well as to alleviate the symptoms or complica-tions associated with the disease, condition or disorder, and prevention of the disease, condi-tion or disorder.
In its broadest sense, the term a "critically ill patient", as used herein refers to a pa-tient who has sustained or are at risk of sustaining acutely life-threatening single or multiple organ system failure due to disease or injury, a patient who is being operated and where complications supervene, and a patient who has been operated in a vital organ within the last week or has been subject to major surgery within the last week. In a more restricted sense, the term a "critically ill patient", as used herein refers to a patient who has sustained or are at risk of sustaining acutely life-threatening single or multiple organ system failure due to dis-ease or injury, or a patient who is being operated and where complications supervene. In an even more restricted sense, the term a "critically ill patient", as used herein refers to a patient who has sustained or are at risk of sustaining acutely life-threatening single or multiple organ system failure due to disease or injury. Similarly, these definitions apply to similar expres-sions such as "critical illness in a patient" and a "patient is critically ill". Examples of a criti-cally ill patient is a patient in need of cardiac surgery, cerebral surgery, thoracic surgery, ab-dominal surgery, vascular surgery, or transplantation, or a patient suffering from neurological diseases, cerebral trauma, respiratory insufficiency, abdominal peritonitis, multiple trauma or severe burns, or critical illness polyneuropathy.
The term "anabolism" as used herein, means the set of metabolic pathways that construct molecules from smaller units. These reactions require energy. One way of categorizing metabolic processes, whether at the cellular, organ or organism level is as 'anabolic' or as 'catabolic', which is the opposite. Anabolism is powered by catabolism, where large molecules are broken down into smaller parts and then used up in respiration. Many anabolic processes are powered by adenosine triphosphate (ATP). Anabolic processes tend toward "building up" organs and tissues. These processes produce growth and differentiation of cells and increase in body size, a process that involves synthesis of complex molecules.
Examples of anabolic processes include the growth and mineralization of bone and increases in muscle mass. Endocrinologists have traditionally classified hormones as anabolic or catabolic, depending on which part of metabolism they stimulate.
The balance between anabolism and catabolism is also regulated by circadian rhythms, with processes such as glucose metabolism fluctuating to match an animal's normal periods of activity throughout the day. Some examples of the "anabolic effects" of these hormones are increased protein synthesis from amino acids, increased appetite, increased bone remodeling and growth, and stimulation of bone marrow, which increases the production of red blood cells. Through a number of mechanisms anabolic hormones stimulate the formation of muscle cells and hence cause an increase in the size of skeletal muscles, leading to increased strength.
In another embodiment, an insulin analogue according to the invention is used as a medicament for delaying or preventing disease progression in type 2 diabetes.
5 In one embodiment of the present invention, the insulin preparation according to the invention is for use as a medicament for the treatment or prevention of hyperglycemia includ-ing stress induced hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabe-tes, and burns, operation wounds and other diseases or injuries where an anabolic effect is needed in the treatment, myocardial infarction, stroke, coronary heart disease and other car-10 diovascular disorders is provided.
In a further embodiment of the present invention, a method for the treatment or pre-vention of hyperglycemia including stress induced hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, and burns, operation wounds and other diseases or inju-ries where an anabolic effect is needed in the treatment, myocardial infarction, coronary 15 heart disease and other cardiovascular disorders, stroke, the method comprising administer-ing to a patient in need of such treatment an effective amount for such treatment of an insulin preparation according to the invention, is provided.
The treatment with an insulin preparation according to the present invention may also be combined with a second or more pharmacologically active substances, e.g. selected from antidiabetic agents, antiobesity agents, appetite regulating agents, antihypertensive agents, agents for the treatment and/or prevention of complications resulting from or associ-ated with diabetes and agents for the treatment and/or prevention of complications and dis-orders resulting from or associated with obesity.
The treatment with an insulin preparation according to the present invention may also be combined with bariatric surgery - a surgery that influences the glucose levels and/or lipid homeostasis such as gastric banding or gastric bypass.
The production of polypeptides, e.g., insulins, is well known in the art. An insulin analogue according to the invention may for instance be produced by classical peptide syn-thesis, e.g. solid phase peptide synthesis using t-Boc or Fmoc chemistry or other well estab-lished techniques, see e.g. Greene and Wuts, "Protective Groups in Organic Synthesis", John Wiley & Sons, 1999. The insulin analogue may also be produced by a method which comprises culturing a host cell containing a DNA sequence encoding the analogue and ca-pable of expressing the insulin analogue in a suitable nutrient medium under conditions per-mitting the expression of the insulin analogue. For insulin analogues comprising non-natural amino acid residues, the recombinant cell should be modified such that the non-natural amino acids are incorporated into the analogue, for instance by use of tRNA
mutants. Hence, briefly, the insulin analogues according to the invention are prepared analogously to the preparation of known insulin analogues.
Several methods may be used for the production of human insulin and human insu-lin analogues. For example three major methods which are used in the production of insulin in microorganisms are disclosed in W02008034881. Two of these involve Escherichia coli, with either the expression of a large fusion protein in the cytoplasm (Frank et al. (1981) in Peptides: Proceedings of the 7th American Peptide Chemistry Symposium (Rich &
Gross, eds.), Pierce Chemical Co., Rockford, III. pp 729-739), or use of a signal peptide to enable secretion into the periplasmic space (Chan et al. (1981) PNAS 78:5401-5404). A
third meth-od utilizes Saccharomyces cerevisiae to secrete an insulin precursor into the medium (Thim et al. (1986) PNAS 83:6766-6770). The prior art discloses a number of insulin precursors which are expressed in either E. coli or Saccharomyces cerevisiae, vide U.55,962,267, WO
95/16708, EP 0055945, EP 0163529, EP 0347845 and EP 0741188.
The insulin analogues are produced by expressing a DNA sequence encoding the insulin analogue in question in a suitable host cell by well known technique as disclosed in e.g. US 6500645. The insulin analogue is either expressed directly or as a precursor mole-cule which has an N-terminal extension on the B-chain or a C-terminal extension on the B-chain. The N-terminal extension may have the function of increasing the yield of the directly expressed product and may be of up to 15 amino acid residues long. The N-terminal exten-sion is to be cleaved of in vitro after isolation from the culture broth and will therefore have a cleavage site next to B1. N-terminal extensions of the type suitable in the present invention are disclosed in US 5,395,922, and EP 765,395. The C-terminal extension may have the function of protecting the mature insulin or insulin analogue molecule against intracellular proteolytic processing by host cell exoproteases. The C-terminal extension is to be cleaved of either extra-cellularly in the culture broth by secreted, active carboxypeptidase or in vitro after isolation from the culture broth. A method for producing mature insulin and insulin ana-logs with C-terminal extensions on the B-chain that are removed by carboxypetidase are dis-closed in WO 08037735. The target insulin product of the process may either be a two-chain human insulin or a two-chain human insulin analogue which may or may not have a short C-terminal extension of the B-chain. If the target insulin product will have no C-terminal exten-sion of the B-chain, then said C-terminal extension should be capable of subsequently being cleaved off from the B-chain before further purification steps.
The present invention also contemplates the following non-limiting list of embodi-ments, which are further described elsewhere herein:
1. An insulin preparation comprising:
= an insulin compound, = a nicotinic compound, and = arginine.
2. The insulin preparation according to embodiment 1, wherein the insulin compound is hu-man insulin or an insulin analog.
3. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is B28Asp human insulin, B3Ly5B29Glu human insulin or B28LysB29Pro human insulin.
4. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is B28Asp human insulin.
5. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is B3Ly5B29Glu human insulin or B28LysB29Pro human insulin.
6. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is B28LysB29Pro human insulin.
7. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is B3Ly5B29Glu human insulin.
8. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in a range selected from the following: 0.1-10.0mM;
0.1-3.0mM; 0.1-2.5mM; 0.1-2.0mM; 0.1-1.5mM; 0.2-2.5mM; 0.2-2.0mM; 0.2-1.5mM; 0.3-3.0mM; 0.3-2.5mM; 0.3-2.0mM; 0.3-1.5mM; 0.5-1.3mM and 0.6-1.2mM.
9. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.1mM to about 10.0mM.
10. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.1mM to about 3.0mM.
11. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.1mM to about 2.5mM.
12. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.1mM to about 2.0mM.
13. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.1mM to about 1.5mM.
14. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.2mM to about 2.5mM.
15. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.2mM to about 2.0mM.
16. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.2mM to about 1.5mM.
17. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.3mM to about 3.0mM.
18. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.3mM to about 2.5mM.
= an insulin compound, = a nicotinic compound, and = arginine.
2. The insulin preparation according to embodiment 1, wherein the insulin compound is hu-man insulin or an insulin analog.
3. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is B28Asp human insulin, B3Ly5B29Glu human insulin or B28LysB29Pro human insulin.
4. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is B28Asp human insulin.
5. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is B3Ly5B29Glu human insulin or B28LysB29Pro human insulin.
6. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is B28LysB29Pro human insulin.
7. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is B3Ly5B29Glu human insulin.
8. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in a range selected from the following: 0.1-10.0mM;
0.1-3.0mM; 0.1-2.5mM; 0.1-2.0mM; 0.1-1.5mM; 0.2-2.5mM; 0.2-2.0mM; 0.2-1.5mM; 0.3-3.0mM; 0.3-2.5mM; 0.3-2.0mM; 0.3-1.5mM; 0.5-1.3mM and 0.6-1.2mM.
9. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.1mM to about 10.0mM.
10. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.1mM to about 3.0mM.
11. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.1mM to about 2.5mM.
12. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.1mM to about 2.0mM.
13. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.1mM to about 1.5mM.
14. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.2mM to about 2.5mM.
15. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.2mM to about 2.0mM.
16. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.2mM to about 1.5mM.
17. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.3mM to about 3.0mM.
18. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.3mM to about 2.5mM.
19. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.3mM to about 2.0mM.
20. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.3mM to about 1.5mM.
21. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.5mM to about 1.3mM.
22. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.3mM to about 1.2mM.
23. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount from about 0.6mM to about 1.2mM.
24. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount of about 0.6 or about 1.2mM.
25. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount of about 0.3mM.
26. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount of about 0.6mM.
27. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount of about 0.9mM.
28. The insulin preparation according to any of the preceding embodiments, wherein the in-sulin compound is present in the amount of about 1.2mM.
29. The insulin preparation according to any of the preceding embodiments, wherein the nic-otinic compound is selected from the group consisting of nicotinamide, nicotinic acid, nia-cm, niacin amide and vitamin B3 and/or salts thereof and/or any combination thereof.
30. The insulin preparation according to any of the preceding embodiments, wherein the nic-otinic compound is selected from nicotinamide and nicotinic acid and/or salts thereof and/or any combination thereof.
31. The insulin preparation according to any of the preceding embodiments, wherein the nic-otinic compound is nicotinamide and/or salts thereof.
32. The insulin preparation according to any of the preceding embodiments, wherein the nic-otinic compound is present in a range selected from the following: 1-300mM; 5-200mM;
40-120mM, 70-140mM or 80-130mM.
40-120mM, 70-140mM or 80-130mM.
33. The insulin preparation according to any of the preceding embodiments, comprising from about 1mM to about 300mM of the nicotinic compound.
34. The insulin preparation according to any of the preceding embodiments, comprising from about 8mM to about 260mM of the nicotinic compound.
35. The insulin preparation according to any of the preceding embodiments, comprising from about 50mM to about 250mM of the nicotinic compound.
36. The insulin preparation according to any of the preceding embodiments, comprising from about 80mM to about 250mM of the nicotinic compound.
37. The insulin preparation according to any of the preceding embodiments, comprising from about 80mM to about 180mM of the nicotinic compound.
38. The insulin preparation according to any of the preceding embodiments, comprising from about 5mM to about 200mM of the nicotinic compound.
39. The insulin preparation according to any of the preceding embodiments, comprising from about 1mM to about 150mM of the nicotinic compound.
40. The insulin preparation according to any of the preceding embodiments, comprising from about 5mM to about 20mM of the nicotinic compound.
41. The insulin preparation according to any of the preceding embodiments, comprising from about 20mM to about 120mM of the nicotinic compound.
42. The insulin preparation according to any of the preceding embodiments, comprising from about 40mM to about 120mM of the nicotinic compound.
43. The insulin preparation according to any of the preceding embodiments, comprising from about 20mM to about 40mM of the nicotinic compound.
44. The insulin preparation according to any of the preceding embodiments, comprising from about 60mM to about 80mM of the nicotinic compound.
45. The insulin preparation according to any of the preceding embodiments, comprising from about 70mM to about 140mM of the nicotinic compound.
46. The insulin preparation according to any of the preceding embodiments, comprising from about 80mM to about 130mM of the nicotinic compound.
47. The insulin preparation according to any of the preceding embodiments, comprising about 8mM, 30mM, 100mM or 130mM of the nicotinic compound.
48. The insulin preparation according to any of the preceding embodiments, comprising about 8mM of the nicotinic compound.
49. The insulin preparation according to any of the preceding embodiments, comprising about 30mM, 100mM or 130mM of the nicotinic compound.
50. The insulin preparation according to any of the preceding embodiments, comprising about 30mM of the nicotinic compound.
5 51. The insulin preparation according to any of the preceding embodiments, comprising about 80mM of the nicotinic compound.
52. The insulin preparation according to any of the preceding embodiments, comprising about 100mM of the nicotinic compound.
53. The insulin preparation according to any of the preceding embodiments, comprising 10 about 120mM of the nicotinic compound.
54. The insulin preparation according to any of the preceding embodiments, comprising about 130mM of the nicotinic compound.
55. The insulin preparation according to any of the preceding embodiments, comprising about 150mM of the nicotinic compound.
15 56. The insulin preparation according to any of the preceding embodiments, comprising about 155mM of the nicotinic compound.
57. The insulin preparation according to any of the preceding embodiments, comprising about 180mM of the nicotinic compound.
58. The insulin preparation according to any of the preceding embodiments, comprising 20 about 230mM of the nicotinic compound.
59. The insulin preparation according to any of the preceding embodiments, comprising the following ranges of arginine compound: 1-100mM, 5-120mM, 8-85mM, 20-90mM, 30-90mM, 30-85mM, 30-60mM or 10-40mM.
60. The insulin preparation according to any of the preceding embodiments, comprising the following ranges of arginine compound: 1-120mM, 8-85mM or 1-40mM.
61. The insulin preparation according to any of the preceding embodiments, comprising from about 1mM to about 120mM of arginine.
62. The insulin preparation according to any of the preceding embodiments, comprising from about 1mM to about 100mM of arginine.
63. The insulin preparation according to any of the preceding embodiments, comprising from about 5mM to about 120mM of arginine.
64. The insulin preparation according to any of the preceding embodiments, comprising from about 20mM to about 90mM of arginine.
65. The insulin preparation according to any of the preceding embodiments, comprising from about 30mM to about 85mM of arginine.
66. The insulin preparation according to any of the preceding embodiments, comprising from about 8mM to about 85mM of arginine.
67. The insulin preparation according to any of the preceding embodiments, comprising from about 30mM to about 60mM of arginine.
68. The insulin preparation according to any of the preceding embodiments, comprising from about 10mM to about 40mM of arginine.
69. The insulin preparation according to any of the preceding embodiments, comprising from about 10mM to about 30mM of arginine.
70. The insulin preparation according to any of the preceding embodiments, comprising from about 10mM to about 60mM of arginine.
71. The insulin preparation according to any of the preceding embodiments, comprising from about 1mM to about 40mM of arginine.
72. The insulin preparation according to any of the preceding embodiments, wherein arginine is present in a range selected from the following: 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 15mM, 20mM, 25mM, 30mM, 35mM or 40mM, 45mM, 50mM, 55mM or 60mM.
73. The insulin preparation according to any of the preceding embodiments, comprising about 1mM of arginine.
74. The insulin preparation according to any of the preceding embodiments, comprising about 2mM of arginine.
75. The insulin preparation according to any of the preceding embodiments, comprising about 3mM of arginine.
76. The insulin preparation according to any of the preceding embodiments, comprising about 4mM of arginine.
77. The insulin preparation according to any of the preceding embodiments, comprising about 5mM of arginine.
78. The insulin preparation according to any of the preceding embodiments, comprising about 6mM of arginine.
79. The insulin preparation according to any of the preceding embodiments, comprising about 7mM of arginine.
80. The insulin preparation according to any of the preceding embodiments, comprising about 8mM of arginine.
81. The insulin preparation according to any of the preceding embodiments, comprising about 9mM of arginine.
82. The insulin preparation according to any of the preceding embodiments, comprising about 10mM of arginine.
83. The insulin preparation according to any of the preceding embodiments, comprising about 11mM of arginine.
84. The insulin preparation according to any of the preceding embodiments, comprising about 12mM of arginine.
85. The insulin preparation according to any of the preceding embodiments, comprising about 13mM of arginine.
86. The insulin preparation according to any of the preceding embodiments, comprising about 14mM of arginine.
87. The insulin preparation according to any of the preceding embodiments, comprising about 15mM of arginine.
88. The insulin preparation according to any of the preceding embodiments, comprising about 17mM of arginine.
89. The insulin preparation according to any of the preceding embodiments, comprising about 20mM of arginine.
90. The insulin preparation according to any of the preceding embodiments, comprising about 22mM of arginine.
91. The insulin preparation according to any of the preceding embodiments, comprising about 25mM of arginine.
92. The insulin preparation according to any of the preceding embodiments, comprising about 30mM of arginine.
93. The insulin preparation according to any of the preceding embodiments, comprising about 35mM of arginine.
94. The insulin preparation according to any of the preceding embodiments, comprising about 40mM of arginine.
95. The insulin preparation according to any of the preceding embodiments, comprising about 45mM of arginine.
96. The insulin preparation according to any of the preceding embodiments, comprising about 50mM of arginine.
97. The insulin preparation according to any of the preceding embodiments, comprising about 55mM of arginine.
98. The insulin preparation according to any of the preceding embodiments, comprising about 60mM of arginine.
99. The insulin preparation according to any of the preceding embodiments, which further comprises a buffer(s).
100. The insulin preparation according to embodiment 99, wherein said buffer is a phos-phate buffer.
101. The insulin preparation according to embodiment 100, comprising from about lmg/mL to about 20mg/mL of phosphate buffer.
102. The insulin preparation according to embodiment 100, comprising from about lmg/mL to about 15mg/mL of phosphate buffer.
103. The insulin preparation according to embodiment 100, comprising from about 1mg/mL to about 10mg/mL of phosphate buffer.
104. The insulin preparation according to embodiment 100, comprising about 3mg/mL of phosphate buffer.
105. The insulin preparation according to embodiment 99, wherein said buffer is Tris.
106. The insulin preparation according to embodiment 105, comprising from about 2mM
to about 50mM of Tris.
107. The insulin preparation according to embodiment 105, comprising from about 10mM
to about 40mM of Tris.
108. The insulin preparation according to embodiment 105, comprising from about 20mM
to about 30mM of Tris.
109. The insulin preparation according to embodiment 105, comprising about 10mM, 20mM, 30mM or 40mM of Tris.
110. The insulin preparation according to embodiment 105, comprising about 7mM of Tris.
111. The insulin preparation according to embodiment 105, comprising about 10mM of Tris.
112. The insulin preparation according to embodiment 105, comprising about 20mM of Tris.
113. The insulin preparation according to embodiment 105, comprising about 30mM of Tris.
114. The insulin preparation according to embodiment 105, comprising about 40mM of Tris.
115. The insulin preparation according to any of the preceding embodiments, which fur-ther comprises a metal ion.
116. The insulin preparation according to embodiment 115, wherein the metal ion is zinc.
117. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is from about 0:6 to about 6:6.
118. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is from about 0:6 to about 5:6.
119. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is from about 1:6 to about 6:6.
120. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is from about 2:6 to about 6:6.
121. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is from about 2:6 to about 5:6.
122. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is from about 2.5:6 to about 4.5:6.
123. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is from about 3:6 to about 4:6.
124. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 2:6.
125. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 2.5:6.
126. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3:6.
127. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.1:6.
128. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.2:6.
129. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.3:6.
130. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.4:6.
131. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.5:6.
132. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.6:6.
133. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.7:6.
134. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.8:6.
135. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.9:6.
136. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 4:6.
137. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 4.5:6.
5 138. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 5:6.
139. The insulin preparation according to any one of the preceding embodiments, which further comprises a stabilizer(s).
140. The insulin preparation according to embodiment 139, wherein the stabilizer is a 10 non-ionic detergent.
141. The insulin preparation according to embodiment 140, wherein the detergent is pol-ysorbate 20 (Tween 20) or polysorbate 80 (Tween 80).
142. The insulin preparation according to embodiment 140, wherein the detergent is pol-ysorbate 20 (Tween 20).
15 143. The insulin preparation according to embodiment 140, wherein the detergent is pol-ysorbate 80 (Tween 80).
144. The insulin preparation according to embodiment 140, comprising from about 5 to 100ppm, from about 10 to about 50ppm or from about 10 to about 20ppm of polysorbate.
145. The insulin preparation according to any one of the preceding embodiments, which 20 further comprises a preservative agent(s).
146. The insulin preparation according to embodiment 145, wherein the preservative is a phenolic compound.
147. The insulin preparation according to embodiment 146, wherein said phenolic com-pound is present in the amount from about 0 to about 6mg/m1 or from about 0 to about 25 4mg/ml.
148. The insulin preparation according to embodiment 146, wherein said phenolic com-pound is present in the amount of from about 5 to about 100mM.
149. The insulin preparation according to embodiment 146, wherein said phenolic com-pound is present in the amount of from about 5 to about 50mM.
150. The insulin preparation according to embodiment 146, wherein said phenolic com-pound is present in the amount of from about 5 to about 30mM.
151. The insulin preparation according to embodiment 146, wherein said phenolic com-pound is present in the amount of about 16mM.
152. The insulin preparation according to embodiment 146, wherein said phenolic com-pound is present in the amount of about 14.4mM.
153. The insulin preparation according to embodiment 145, wherein said preservative is m-cresol.
154. The insulin preparation according to embodiment 153, wherein m-cresol is present in the amount from about 0.5 to about 4.0mg/m1 or from about 0.6 to about 4.0mg/ml.
155. The insulin preparation according to embodiment 153, wherein m-cresol is present in the amount of from about 5 to about 100mM.
156. The insulin preparation according to embodiment 153, wherein m-cresol is present in the amount of from about 5 to about 50mM.
157. The insulin preparation according to embodiment 153, wherein m-cresol is present in the amount of from about 5 to about 30mM.
158. The insulin preparation according to embodiment 153, wherein m-cresol is present in the amount of about 16mM.
159. The insulin preparation according to embodiment 153, wherein m-cresol is present in the amount of about 14.4mM.
160. The insulin preparation according to any of the preceding embodiments, further comprising glycerol in the amount from about 0.5 to about 2.5%.
161. The insulin preparation according to any of the preceding embodiments, further comprising glycerol in the amount from about 0.7 to about 2.0%.
162. The insulin preparation according to any of the preceding embodiments, further comprising glycerol in the amount from about 1.0 to about 1.5%.
163. The insulin preparation according to any of the preceding embodiments, further comprising glycerol in the amount of about 1.25%.
164. The insulin preparation according to any of the preceding embodiments, wherein the pH is neutral to weakly basic.
165. The insulin preparation according to any of the preceding embodiments, wherein the pH is from about 6.8 to about 8Ø
166. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 6.8.
167. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 6.9.
168. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7Ø
169. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.1.
170. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.2.
171. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.3.
172. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.4.
173. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.5.
174. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.6.
175. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.7.
176. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.8.
177. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.9.
178. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 8Ø
179. A method of reducing the blood glucose level in mammals by administering to a pa-tient in need of such treatment a therapeutically active dose of an insulin preparation ac-cording to any of the preceding embodiments.
180. A method for the treatment of diabetes mellitus in a subject comprising administer-ing to a subject an insulin preparation according to any of embodiments 1-178.
181. A method according to any of embodiments 179-180, for parenteral administration.
182. An insulin preparation according to any of embodiments 1-178, for use in the treat-ment or prevention of hyperglycemia including stress induced hyperglycemia, type 2 dia-betes, impaired glucose tolerance, type 1 diabetes, and burns, operation wounds and other diseases or injuries where an anabolic effect is needed in the treatment, myocardial infarction, stroke, coronary heart disease and other cardiovascular disorders and treat-ment of critically ill diabetic and non-diabetic patients.
183. The insulin preparation according to embodiment 182, for use in the treatment or prevention of hyperglycemia including stress induced hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, and burns and operation wounds, myocar-dial infarction, stroke, coronary heart disease and other cardiovascular disorders.
184. The insulin preparation according to embodiment 182-183, for use in the treatment of hyperglycemia type 2 diabetes and type 1 diabetes.
185. An insulin preparation comprising:
= an insulin compound, =a nicotinic compound =arginine, and =a buffer.
186. The insulin preparation according to embodiment 185, wherein the insulin com-pound is human insulin or an insulin analog.
187. The insulin preparation according to any one of embodiments 185 or 186, wherein the insulin compound is selected from the group consisting of B28Asp human insulin, B3Ly5B29Glu human insulin and B28LysB29Pro.
188. The insulin preparation according to embodiment 186, wherein the insulin com-pound is B28Asp human insulin.
189. The insulin preparation according to any one of embodiments 185-188, wherein the insulin compound is present in the amount from about 0.2mM to about 2.0mM.
190. The insulin preparation according to any one of embodiments 185-189, wherein the insulin compound is present in the amount from about 0.6mM to about 1.2mM.
191. The insulin preparation according to any one of embodiments 185-190, wherein the nicotinic compound is selected from the group consisting of nicotinamide, nicotinic acid, niacin, niacin amide and vitamin B3 and/or salts thereof and/or any combination thereof.
192. The insulin preparation according to any one of embodiments 185-191, wherein the nicotinic compound is nicotinamide.
193. The insulin preparation according to embodiment 192, comprising from about 1mM
to about 250mM of the nicotinic compound.
194. The insulin preparation according to embodiment 192, comprising from about 1mM
to about 250mM of the nicotinic compound.
195. The insulin preparation according to embodiment 192, comprising from about 80mM
to about 230mM of the nicotinic compound.
196. The insulin preparation according to any one of embodiments 185-195, comprising from about 10mM to about 60mM of arginine.
197. The insulin preparation according to any one of embodiments 185-196, comprising from about 10mM to about 30mM of arginine.
198. The insulin preparation according to any one of embodiments 185-197, comprising about 20mM arginine.
199. The insulin preparation according to any one of embodiments 185-198, wherein said buffer is a phosphate buffer.
200. The insulin preparation according to any one of embodiments 185-199, wherein said buffer is Tris.
201. The insulin preparation according to any one of embodiments 185-200, which may further comprises preservative agent(s), isotonicity agent(s) and/or stabilizer(s).
202. The insulin preparation according to any one of embodiments 185-201, which further comprises a metal ion.
203. The insulin preparation according to embodiment 202, wherein the metal ion is zinc.
204. The insulin preparation according to embodiment 203, wherein the zinc:insulin molar ratio is from about 0:6 to about 3.5:6.
205. The insulin preparation according to embodiment 203, wherein the zinc:insulin molar ratio is from about 2:6 to about 3:6.
206. The insulin preparation according to any one of embodiments 185-205, wherein the preparation has a pH of less than 7.4.
207. The insulin preparation according to any one of embodiments 185-205, wherein the preparation has a pH of about 7.4.
208. The insulin preparation according to any one of embodiments 185-205, wherein the preparation has a pH of about 7.1 209. An insulin preparation comprising: B28Asp human insulin; nicotinamide;
zinc; argin-ine; and a phosphate buffer.
210. The insulin preparation of embodiment 209, wherein the B28Asp human insulin is present in a concentration ranging from about 0.6 mM to about 1.2 mM, and wherein the nicotinamide is present at a concentration ranging from about 80 mM to about 260 mM, and wherein the arginine is present in a concentration ranging from about 10 mM to about 40 mM, and wherein less than about 4 zinc ions are present per six B28Asp human insulin molecules, and wherein the preparation has a pH of about 7.4 or less.
211. An insulin preparation consisting essentially of:
a. B28Asp human insulin, wherein the B28Asp human insulin is present in a concentration ranging from about 0.6 mM to about 1.2 mM;
b. Nicotinamide, wherein the nicotinamide is present in a concentration ranging from about 80 mM to abour 260 mM;
c. Zinc, wherein less than about 4 zinc ions are present per six B28Asp human insulin molecules;
d. Arginine, wherein the the arginine is present in a concentration ranging from about 10 mM to about 30 mM; and e. a phosphate buffer;
wherein the preparation has a pH of about 7.1.
212. A method of reducing the blood glucose level in mammals by administering to a mammal in need of such treatment a therapeutically active dose of an insulin preparation according to any one of the preceding embodiments.
5 213. A method for the treatment of diabetes mellitus in a subject comprising administer-ing to a subject an insulin preparation according to any one of embodiments 1-211.
214. An insulin preparation according to any one of embodiments 1-211, for use in the treatment or prevention of hyperglycemia including stress induced hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, and burns, operation wounds and 10 other diseases or injuries where an anabolic effect is needed in the treatment, myocardial infarction, stroke, coronary heart disease and other cardiovascular disorders and treat-ment of critically ill diabetic and non-diabetic patients.
215. An insulin preparation according to any one of embodiments 1-211, for use in the treatment of hyperglycemia type 2 diabetes and type 1 diabetes.
Further embodiments of the invention relate to the following:
216. An insulin preparation comprising:
= an insulin compound, = a nicotinic compound, and = arginine.
217. The insulin preparation according to embodiment 216, wherein the insulin com-pound is human insulin or an insulin analog.
218. The insulin preparation according to embodiments 216-217, wherein the insulin compound is B28Asp human insulin.
219. The insulin preparation according to any one of embodiments 216-218, wherein the insulin compound is B28LysB29Pro human insulin.
220. The insulin preparation according to any one of embodiments 216-219, wherein the insulin compound is B3Ly5B29Glu human insulin.
221. The insulin preparation according to any one of embodiments 216-220, wherein the insulin compound is present in the amount from about 0.2mM to about 2.0mM.
222. The insulin preparation according to any one of embodiments 216-221, wherein the insulin compound is present in the amount from about 0.3mM to about 1.2mM.
223. The insulin preparation according to any one of embodiments 216-222, wherein the nicotinic compound is selected from the group consisting of nicotinamide, nicotinic acid, niacin, niacin amide and vitamin B3 and/or salts thereof and/or any combination thereof.
224. The insulin preparation according to any one of embodiments 216-223, comprising from about 1mM to about 150mM of the nicotinic compound.
225. The insulin preparation according to any one of embodiments 216-224, comprising from about 1mM to about 85mM of arginine.
226. The insulin preparation according to any one of 216-225, which further comprises a metal ion, preservative agent(s), isotonicity agent(s) and stabilizer(s) and buffer(s).
227. A method of reducing the blood glucose level in mammals by administering to a pa-tient in need of such treatment a therapeutically active dose of an insulin preparation ac-cording to any one of embodiments 216-226.
228. A method for the treatment of diabetes mellitus in a subject comprising administer-ing to a subject an insulin preparation according to any one of embodiments 216-226.
229. An insulin preparation according to any one of embodiments 216-226, for use in the treatment or prevention of hyperglycemia including stress induced hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, and burns, operation wounds and other diseases or injuries where an anabolic effect is needed in the treatment, myocardial infarction, stroke, coronary heart disease and other cardiovascular disorders and treat-ment of critically ill diabetic and non-diabetic patients.
The invention is further illustrated by the following examples which are not to be construed as limiting.
All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each refer-ence were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law).
All headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.
The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the inven-tion.
The citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability, and/or enforceability of such patent documents.
This invention includes all modifications and equivalents of the subject matter re-cited in the claims appended hereto as permitted by applicable law.
EXAMPLES
Example 1 Preparation of pharmaceutical preparations The pharmaceutical preparations of the present invention may be formulated as an aqueous solution. The aqueous medium is made isotonic, for example, with sodium chloride or glyc-erol. Furthermore, the aqueous medium may contain zinc ions, for example added as zinc acetate or zinc chloride, buffers and preservatives. Arginine may be added as Arg, HCI. The pH value of the preparation is adjusted to the desired value and may be between about 3 to about 8.5, between about 3 and about 5 or about 6.5 and about 7.5 depending on the isoe-lectric point, pl, of the insulin in question.
Table 1. Composition of insulin preparations according to this invention Insulin Zn Phenol m- NaCI Phos- Tris Glyce- Arginine, Nicotin-Glutamic pH
aspart (mM) (mM) cresol (mM) phate (mM) rol HCI amide acid (mM) (mM) (mM) (%w/v) (mM) (mM) (mM) A* 0.6 0.3 16 16 10 7 1.6 7.4 B 0.6 0.3 16 16 2 7 130 7.4 C 0.6 0.3 16 16 2 7 50 80 50 7.4 D 0.6 0.3 16 16 2 7 130 7.4 E 0.6 0.3 16 16 2 7 50 80 50 7.4 F 0.6 0.3 16 16 20 7 30 80 30 7.4 G 0.6 0.3 16 16 20 7 30 80 30 7.4 H
1.2 0.6 16 16 20 7 30 80 30 7.4 I 1.2 0.6 16 16 20 7 30 80 30 7.4 J 0.6 0.3 16 16 10 7 1.3 80 7.4 K 0.6 0.3 16 16 10 7 0.77 30 80 7.4 L 0.6 0.3 16 16 10 7 0.24 30 80 30 7.4 M 0.6 0.3 16 16 10 7 60 100 7.4 N 0.6 0.3 16 16 10 7 1.13 100 7.4 * Commercially available NovoRapid Table 2. Composition of further insulin preparations according to this invention Preparation [Insulin [Zn2+] [phenol] [Arg] [Gly] [Glu] [His] [Nicotin pH
nr. aspart] mM mM mM mM mM mM amide]
mM mM
1 0.6 0.3 32 260 7.4 2 0.6 0.3 32 10 260 7.4 3 0.6 0.3 32 20 260 7.4 4 0.6 0.3 32 30 260 7.4 0.6 0.3 32 40 260 7.4 6 0.6 0.3 32 50 260 7.4 7 0.6 0.3 32 50 260 7.4 8 0.6 0.3 32 50 260 7.4 9 0.6 0.3 32 50 260 7.4 Table 3. Composition of further insulin preparations according to this invention Preparation [Insulin [Zn2+] [phenol] [m- [Arg] [Glycerol] [tris] [Nicotin pH
nr. aspart] mM mM cresol] mM %w/vol mM amide]
mM mM mM
10 0.6 0.35 16 16 1.3 7 80 7.4 11 0.6 0.35 16 16 10 1.3 7 80 7.4 12 0.6 0.35 16 16 30 1.3 7 80 7.4 13 0.6 0.35 16 16 50 1.3 7 80 7.4 Table 4. Composition of further insulin preparations according to this invention Preparation [Insulin [Zn2+] [phenol] [m- [Arg] [Glycerol]
[Phos- [Nicotin pH
nr. aspart] mM mM mM cresol] mM %w/vol phate]
amide] mM
mM mg/mL
14 0.6 0.30 16 16 20 1.08 3 80 7.1 15 0.6 0.30 16 16 20 - 3 230 7.1 16 0.6 0.20 16 16 20 - 3 230 7.1 17 0.6 0.24 16 16 20 0.24 3 180 7.1 18 0.6 0.28 16 16 20 0.45 3 155 7.1 19 0.6 0.25 16 16 20 0.75 3 120 7.1 20 0.6 0.20 16 16 20 1.08 3 80 7.1 10 Example 2 Analysis of insulin chemical stability Size Exclusion Chromatography Quantitative determination of high molecular weight protein (HMWP) and monomer insulin 15 aspart was performed on Waters insulin (300 x 7.8mm, part nr wat 201549) with an eluent containing 2.5M acetic acid, 4mM L-arginine and 20 %(VN) acetonitrile at a flow rate of 1m1/min. and 40 C. Detection was performed with a tuneable absorbance detector (Waters 486) at 276nm. Injection volume was 40p1 and a 600pM human insulin standard.
HMWP and concentration of the preparations were measured at each sampling point.
Reverse phase chromatography (U PLC) Determination of the insulin aspart related impurities were performed on a UPLC system us-ing a BEH RP 082.1 x 100mm column, particle size of 1,7pm. Waters part no 186002878.
with a flow rate of 0,5m1/min., at 40 C detection at 220nm. Elution was performed with a mobile phase consisting of the following:
A. 10 % (w/V) acetonititrile, 2.8% (w/w) sodium sulphate, 0.3 % (w/w) o-phosphoric acid, pH 3.5.
B. 70 % (w/V) acetonitrile. Gradient: 0-11 min isocratic with 73%/27% of NB, linear change to 52%148% NB, 13-15 min. linear change to 73%/27% of NB, 15-20 min. iso-cratic gradient at 73%/27% of NB.
The amount of B28iso-aspartate, desamido and other related impurities were de-termined as absorbance area measured in percent of total absorbance area determined after elution of the preservatives. The RP-UPLC method is equivalent to the analytical method used for quality control of Novo Nordisk marketed insulin aspart pharmaceuticals.
Addition of arginine reduces the amount of degradation products formed, especially HMWP and des-amido forms, increasing the concentration of arginine in the range 10 to 50mM leads to further reduction of degradation. The physical stability measured as lag time in the ThT assay is reduced upon addition of arginine and is increasingly reduced when the arginine concentration is increased. The overall performance of 50mM arginine is superior to 50 mM glycine, 50mM glutamic acid, or 50mM histidine regarding reduction of the formation of degradation products, as is shown in Table 4 below.
The insulin preparations of the present invention provide fast-acting insulin prepara-tions which are not only physically stable, but surprisingly also chemically stable.
Table 5. Physical and chemical stability data for insulin preparations 1-9 of Table 2 Preparation nr. Physical stabil- Chemical stability ity, lag time Content of degradation product (%) measured as differ-(min) in ThT ence between content after incubation for 2 weeks at assay 37 C and at 4 C
B28 !soAsp des-amido Other re- HMWP
forms lated impuri-ties 1 160 1.17 3.67 1.73 1.36 2 80 1.30 3.05 0.82 0.65 3 80 1.30 2.49 0.64 0.34 4 60 1.31 2.26 0.79 0.20 60 1.27 2.27 0.37 0.19 6 40 1.36 1.99 0.47 0.16 7 100 1.26 4.72 2.21 1.11 8 50 1.39 3.41 1.07 0.70 9 0 1.75 6.99 2.22 1.01 Table 6. Chemical stability data for insulin preparations 10-13 of Table 3 Preparation nr. Chemical stability Content of degradation product (%) measured as differ-ence between content after incubation for 2 weeks at 37 C and at 4 C
B28 !soAsp des-amido Other re- HMWP
forms lated impuri-ties 1.35 1.90 1.71 0.91 11 1.45 1.44 0.98 0.39 12 1.43 1.07 0.75 0.21 13 1.46 0.99 0.84 0.16 Table 7. Physical and chemical stability data for insulin preparations 14-20 of Table 4 Preparation Physical stabil- Chemical stability 5 nr. ity, lag time Content of degradation product ( /0) measured after incu-(min) in ThT bation for 4 weeks at 37 C
assay B28 !soAsp desamido Other related HMWP
forms impurities 14 133 2.7 2.9 2.1 0.4 15 87 2.7 3.6 2.3 0.4 16 50 2.8 4.4 2.7 0.4 17 65 2.7 3.5 2.3 0.4 18 107 2.7 3.3 2.2 0.5 19 85 2.6 3.1 2.3 0.5 20 59 2.6 3.3 2.3 0.5 Example 3 Pharmacokinetic (PK)/ Pharmacodynamic (PD) studies in LYD pig model and plasma analysis assay PK/PD studies in LYD pigs The PK/PD studies were performed on domestic female pigs, LYD cross-breed, weighing between 55 and 110kg. The pigs were catheterised into the jugular vein through an ear vein at least 2 days before start of the study. The last meal before the start of the study was served to the animals approx. 18 hours prior to the injection of the test preparation, and the animals had free access to water at all time during the fasting period and the test period.
At time 0 hours the test preparation was given subcutaneous on the lateral side of the neck.
A blood sample was drawn prior dosing and at regular time intervals after dosing samples were drawn from the catheter and sampled into 1.5m1 glass tubes pre-coated with heparin.
The blood samples were kept in ice water until separation of plasma by centrifugation for 10min. 3000rpm at 4 C, which was done within the first 30 minutes. Plasma samples were stored at 4 C for short time (2-3 hours) or at -18 C for long term storage and were analysed for glucose on YSI or Konelab 30i and for insulin Aspart concentration by LOCI.
Luminescent Oxygen Channeling Immunoassay (LOCI) for Insulin Aspart quantification The insulin Aspart LOCI is a monoclonal antibody-based sandwich immunoassay and ap-plies the proximity of two beads, the europium-coated acceptor beads and the streptavidin coated donor-beads. The acceptor beads were coated with a specific antibody against hu-man insulin and recognize insulin Aspart in plasma samples. A second biotinylated antibody bind specific to insulin Aspart and together with the streptavidin coated beads, they make up the sandwich. Illumination of the beads-aggregate-immunocomplex releases singlet oxygen from the donor beads which channels into the acceptor beads and triggers chemilumines-cence. The chemiluminescence was measured and the amount of light generated is propor-tional to the concentration of insulin Aspart.
Compared to the marketed product NovoRapid , the initial rate of plasma glucose lowering is faster for the preparations of the present invention (Figures 3 and 4).
Likewise, when com-pared to NovoRapid , the initial absorption rate of the insulin component of the preparations of the present invention, is markedly faster (Figure 5).
5 Example 4 General introduction to ThT fibrillation assays for the assessment of physical stability of protein formulations Low physical stability of a peptide may lead to amyloid fibril formation, which is observed as well-ordered, thread-like macromolecular structures in the sample eventually resulting in gel 10 formation. This has traditionally been measured by visual inspection of the sample. However, that kind of measurement is very subjective and depending on the observer.
Therefore, the application of a small molecule indicator probe is much more advantageous.
Thioflavin T
(ThT) is such a probe and has a distinct fluorescence signature when binding to fibrils [Naiki et al. (1989) Anal. Biochem. 177, 244-249; LeVine (1999) Methods. Enzymol.
309, 274-284].
15 The time course for fibril formation can be described by a sigmoidal curve with the following expression [Nielsen et al. (2001) Biochemistry 40, 6036-6046];
f +m ft F = f, + m,t + ________________ ), 1+e t" Eq.(i) 20 Here, F is the ThT fluorescence at the time t. The constant to is the time needed to reach 50% of maximum fluorescence. The two important parameters describing fibril forma-tion are the lag-time calculated by to ¨ 2T and the apparent rate constant kapp =
= = = ==
==
.= = ff + mft c.) c.) - =
o kapp = lit f, H
- f, + mIt =
-111111111111p111111111111 to Ti me Lag-time = to -Formation of a partially folded intermediate of the peptide is suggested as a general initiating mechanism for fibrillation. Few of those intermediates nucleate to form a template onto which further intermediates may assembly and the fibrillation proceeds.
The lag-time corresponds to the interval in which the critical mass of nucleus is built up and the apparent rate constant is the rate with which the fibril itself is formed.
Sample preparation Samples were prepared freshly before each assay. Each sample composition is described in each example. The pH of the sample was adjusted to the desired value using appropriate amounts of concentrated NaOH and HCIator HCI. Thioflavin T was added to the samples from a stock solution in H20 to a final concentration of 1 M.
Sample aliquots of 2000 were placed in a 96 well microtiter plate (Packard Opti-PlateTm-96, white polystyrene). Usually, four or eight replica of each sample (corresponding to one test condition) were placed in one column of wells. The plate was sealed with Scotch Pad (Qiagen).
Incubation and fluorescence measurement Incubation at given temperature, shaking and measurement of the ThT
fluorescence emis-sion were done in a Fluoroskan Ascent FL fluorescence platereader or Varioskan platereader (Thermo Labsystems). The temperature was adjusted to 37 C. The orbital shaking was ad-justed to 960rpm with an amplitude of 1mm in all the presented data.
Fluorescence meas-urement was done using excitation through a 444nm filter and measurement of emission through a 485nm filter.
Each run was initiated by incubating the plate at the assay temperature for 10 min.
The plate was measured every 20 minutes for a desired period of time. Between each meas-urement, the plate was shaken and heated as described.
Data handling The measurement points were saved in Microsoft Excel format for further processing and curve drawing and fitting was performed using GraphPad Prism. The background emission from ThT in the absence of fibrils was negligible. The data points are typically a mean of four or eight samples and shown with standard deviation error bars. Only data obtained in the same experiment (i.e. samples on the same plate) are presented in the same graph ensuring a relative measure of fibrillation between experiments.
The data set may be fitted to Eq. (1). However, since full sigmodial curves are not always achieved during the measurement time, lag times were here visually determined from the ThT fluorescence curve as the time point at which the ThT fluorescence is different than the background level.
Measurement of initial and final concentrations The peptide concentration in each of the tested formulations were measured both before ap-plication in the ThT fibrillation assay ("Initial") and after completion of the ThT fibrillation ("Af-ter ThT assay"). Concentrations were determined by reverse HPLC methods using a pramlin-tide standard as a reference. Before measurement after completion 150p1 was collected from each of the replica and transferred to an Eppendorf tube. These were centrifuged at 30000 G
for 40mins. The supernatants were filtered through a 0.22pm filter before application on the HPLC system.
5 51. The insulin preparation according to any of the preceding embodiments, comprising about 80mM of the nicotinic compound.
52. The insulin preparation according to any of the preceding embodiments, comprising about 100mM of the nicotinic compound.
53. The insulin preparation according to any of the preceding embodiments, comprising 10 about 120mM of the nicotinic compound.
54. The insulin preparation according to any of the preceding embodiments, comprising about 130mM of the nicotinic compound.
55. The insulin preparation according to any of the preceding embodiments, comprising about 150mM of the nicotinic compound.
15 56. The insulin preparation according to any of the preceding embodiments, comprising about 155mM of the nicotinic compound.
57. The insulin preparation according to any of the preceding embodiments, comprising about 180mM of the nicotinic compound.
58. The insulin preparation according to any of the preceding embodiments, comprising 20 about 230mM of the nicotinic compound.
59. The insulin preparation according to any of the preceding embodiments, comprising the following ranges of arginine compound: 1-100mM, 5-120mM, 8-85mM, 20-90mM, 30-90mM, 30-85mM, 30-60mM or 10-40mM.
60. The insulin preparation according to any of the preceding embodiments, comprising the following ranges of arginine compound: 1-120mM, 8-85mM or 1-40mM.
61. The insulin preparation according to any of the preceding embodiments, comprising from about 1mM to about 120mM of arginine.
62. The insulin preparation according to any of the preceding embodiments, comprising from about 1mM to about 100mM of arginine.
63. The insulin preparation according to any of the preceding embodiments, comprising from about 5mM to about 120mM of arginine.
64. The insulin preparation according to any of the preceding embodiments, comprising from about 20mM to about 90mM of arginine.
65. The insulin preparation according to any of the preceding embodiments, comprising from about 30mM to about 85mM of arginine.
66. The insulin preparation according to any of the preceding embodiments, comprising from about 8mM to about 85mM of arginine.
67. The insulin preparation according to any of the preceding embodiments, comprising from about 30mM to about 60mM of arginine.
68. The insulin preparation according to any of the preceding embodiments, comprising from about 10mM to about 40mM of arginine.
69. The insulin preparation according to any of the preceding embodiments, comprising from about 10mM to about 30mM of arginine.
70. The insulin preparation according to any of the preceding embodiments, comprising from about 10mM to about 60mM of arginine.
71. The insulin preparation according to any of the preceding embodiments, comprising from about 1mM to about 40mM of arginine.
72. The insulin preparation according to any of the preceding embodiments, wherein arginine is present in a range selected from the following: 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 15mM, 20mM, 25mM, 30mM, 35mM or 40mM, 45mM, 50mM, 55mM or 60mM.
73. The insulin preparation according to any of the preceding embodiments, comprising about 1mM of arginine.
74. The insulin preparation according to any of the preceding embodiments, comprising about 2mM of arginine.
75. The insulin preparation according to any of the preceding embodiments, comprising about 3mM of arginine.
76. The insulin preparation according to any of the preceding embodiments, comprising about 4mM of arginine.
77. The insulin preparation according to any of the preceding embodiments, comprising about 5mM of arginine.
78. The insulin preparation according to any of the preceding embodiments, comprising about 6mM of arginine.
79. The insulin preparation according to any of the preceding embodiments, comprising about 7mM of arginine.
80. The insulin preparation according to any of the preceding embodiments, comprising about 8mM of arginine.
81. The insulin preparation according to any of the preceding embodiments, comprising about 9mM of arginine.
82. The insulin preparation according to any of the preceding embodiments, comprising about 10mM of arginine.
83. The insulin preparation according to any of the preceding embodiments, comprising about 11mM of arginine.
84. The insulin preparation according to any of the preceding embodiments, comprising about 12mM of arginine.
85. The insulin preparation according to any of the preceding embodiments, comprising about 13mM of arginine.
86. The insulin preparation according to any of the preceding embodiments, comprising about 14mM of arginine.
87. The insulin preparation according to any of the preceding embodiments, comprising about 15mM of arginine.
88. The insulin preparation according to any of the preceding embodiments, comprising about 17mM of arginine.
89. The insulin preparation according to any of the preceding embodiments, comprising about 20mM of arginine.
90. The insulin preparation according to any of the preceding embodiments, comprising about 22mM of arginine.
91. The insulin preparation according to any of the preceding embodiments, comprising about 25mM of arginine.
92. The insulin preparation according to any of the preceding embodiments, comprising about 30mM of arginine.
93. The insulin preparation according to any of the preceding embodiments, comprising about 35mM of arginine.
94. The insulin preparation according to any of the preceding embodiments, comprising about 40mM of arginine.
95. The insulin preparation according to any of the preceding embodiments, comprising about 45mM of arginine.
96. The insulin preparation according to any of the preceding embodiments, comprising about 50mM of arginine.
97. The insulin preparation according to any of the preceding embodiments, comprising about 55mM of arginine.
98. The insulin preparation according to any of the preceding embodiments, comprising about 60mM of arginine.
99. The insulin preparation according to any of the preceding embodiments, which further comprises a buffer(s).
100. The insulin preparation according to embodiment 99, wherein said buffer is a phos-phate buffer.
101. The insulin preparation according to embodiment 100, comprising from about lmg/mL to about 20mg/mL of phosphate buffer.
102. The insulin preparation according to embodiment 100, comprising from about lmg/mL to about 15mg/mL of phosphate buffer.
103. The insulin preparation according to embodiment 100, comprising from about 1mg/mL to about 10mg/mL of phosphate buffer.
104. The insulin preparation according to embodiment 100, comprising about 3mg/mL of phosphate buffer.
105. The insulin preparation according to embodiment 99, wherein said buffer is Tris.
106. The insulin preparation according to embodiment 105, comprising from about 2mM
to about 50mM of Tris.
107. The insulin preparation according to embodiment 105, comprising from about 10mM
to about 40mM of Tris.
108. The insulin preparation according to embodiment 105, comprising from about 20mM
to about 30mM of Tris.
109. The insulin preparation according to embodiment 105, comprising about 10mM, 20mM, 30mM or 40mM of Tris.
110. The insulin preparation according to embodiment 105, comprising about 7mM of Tris.
111. The insulin preparation according to embodiment 105, comprising about 10mM of Tris.
112. The insulin preparation according to embodiment 105, comprising about 20mM of Tris.
113. The insulin preparation according to embodiment 105, comprising about 30mM of Tris.
114. The insulin preparation according to embodiment 105, comprising about 40mM of Tris.
115. The insulin preparation according to any of the preceding embodiments, which fur-ther comprises a metal ion.
116. The insulin preparation according to embodiment 115, wherein the metal ion is zinc.
117. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is from about 0:6 to about 6:6.
118. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is from about 0:6 to about 5:6.
119. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is from about 1:6 to about 6:6.
120. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is from about 2:6 to about 6:6.
121. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is from about 2:6 to about 5:6.
122. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is from about 2.5:6 to about 4.5:6.
123. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is from about 3:6 to about 4:6.
124. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 2:6.
125. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 2.5:6.
126. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3:6.
127. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.1:6.
128. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.2:6.
129. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.3:6.
130. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.4:6.
131. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.5:6.
132. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.6:6.
133. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.7:6.
134. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.8:6.
135. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 3.9:6.
136. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 4:6.
137. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 4.5:6.
5 138. The insulin preparation according to embodiment 116, wherein the zinc:insulin molar ratio is about 5:6.
139. The insulin preparation according to any one of the preceding embodiments, which further comprises a stabilizer(s).
140. The insulin preparation according to embodiment 139, wherein the stabilizer is a 10 non-ionic detergent.
141. The insulin preparation according to embodiment 140, wherein the detergent is pol-ysorbate 20 (Tween 20) or polysorbate 80 (Tween 80).
142. The insulin preparation according to embodiment 140, wherein the detergent is pol-ysorbate 20 (Tween 20).
15 143. The insulin preparation according to embodiment 140, wherein the detergent is pol-ysorbate 80 (Tween 80).
144. The insulin preparation according to embodiment 140, comprising from about 5 to 100ppm, from about 10 to about 50ppm or from about 10 to about 20ppm of polysorbate.
145. The insulin preparation according to any one of the preceding embodiments, which 20 further comprises a preservative agent(s).
146. The insulin preparation according to embodiment 145, wherein the preservative is a phenolic compound.
147. The insulin preparation according to embodiment 146, wherein said phenolic com-pound is present in the amount from about 0 to about 6mg/m1 or from about 0 to about 25 4mg/ml.
148. The insulin preparation according to embodiment 146, wherein said phenolic com-pound is present in the amount of from about 5 to about 100mM.
149. The insulin preparation according to embodiment 146, wherein said phenolic com-pound is present in the amount of from about 5 to about 50mM.
150. The insulin preparation according to embodiment 146, wherein said phenolic com-pound is present in the amount of from about 5 to about 30mM.
151. The insulin preparation according to embodiment 146, wherein said phenolic com-pound is present in the amount of about 16mM.
152. The insulin preparation according to embodiment 146, wherein said phenolic com-pound is present in the amount of about 14.4mM.
153. The insulin preparation according to embodiment 145, wherein said preservative is m-cresol.
154. The insulin preparation according to embodiment 153, wherein m-cresol is present in the amount from about 0.5 to about 4.0mg/m1 or from about 0.6 to about 4.0mg/ml.
155. The insulin preparation according to embodiment 153, wherein m-cresol is present in the amount of from about 5 to about 100mM.
156. The insulin preparation according to embodiment 153, wherein m-cresol is present in the amount of from about 5 to about 50mM.
157. The insulin preparation according to embodiment 153, wherein m-cresol is present in the amount of from about 5 to about 30mM.
158. The insulin preparation according to embodiment 153, wherein m-cresol is present in the amount of about 16mM.
159. The insulin preparation according to embodiment 153, wherein m-cresol is present in the amount of about 14.4mM.
160. The insulin preparation according to any of the preceding embodiments, further comprising glycerol in the amount from about 0.5 to about 2.5%.
161. The insulin preparation according to any of the preceding embodiments, further comprising glycerol in the amount from about 0.7 to about 2.0%.
162. The insulin preparation according to any of the preceding embodiments, further comprising glycerol in the amount from about 1.0 to about 1.5%.
163. The insulin preparation according to any of the preceding embodiments, further comprising glycerol in the amount of about 1.25%.
164. The insulin preparation according to any of the preceding embodiments, wherein the pH is neutral to weakly basic.
165. The insulin preparation according to any of the preceding embodiments, wherein the pH is from about 6.8 to about 8Ø
166. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 6.8.
167. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 6.9.
168. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7Ø
169. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.1.
170. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.2.
171. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.3.
172. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.4.
173. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.5.
174. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.6.
175. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.7.
176. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.8.
177. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 7.9.
178. The insulin preparation according to any of the preceding embodiments, wherein the pH is about 8Ø
179. A method of reducing the blood glucose level in mammals by administering to a pa-tient in need of such treatment a therapeutically active dose of an insulin preparation ac-cording to any of the preceding embodiments.
180. A method for the treatment of diabetes mellitus in a subject comprising administer-ing to a subject an insulin preparation according to any of embodiments 1-178.
181. A method according to any of embodiments 179-180, for parenteral administration.
182. An insulin preparation according to any of embodiments 1-178, for use in the treat-ment or prevention of hyperglycemia including stress induced hyperglycemia, type 2 dia-betes, impaired glucose tolerance, type 1 diabetes, and burns, operation wounds and other diseases or injuries where an anabolic effect is needed in the treatment, myocardial infarction, stroke, coronary heart disease and other cardiovascular disorders and treat-ment of critically ill diabetic and non-diabetic patients.
183. The insulin preparation according to embodiment 182, for use in the treatment or prevention of hyperglycemia including stress induced hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, and burns and operation wounds, myocar-dial infarction, stroke, coronary heart disease and other cardiovascular disorders.
184. The insulin preparation according to embodiment 182-183, for use in the treatment of hyperglycemia type 2 diabetes and type 1 diabetes.
185. An insulin preparation comprising:
= an insulin compound, =a nicotinic compound =arginine, and =a buffer.
186. The insulin preparation according to embodiment 185, wherein the insulin com-pound is human insulin or an insulin analog.
187. The insulin preparation according to any one of embodiments 185 or 186, wherein the insulin compound is selected from the group consisting of B28Asp human insulin, B3Ly5B29Glu human insulin and B28LysB29Pro.
188. The insulin preparation according to embodiment 186, wherein the insulin com-pound is B28Asp human insulin.
189. The insulin preparation according to any one of embodiments 185-188, wherein the insulin compound is present in the amount from about 0.2mM to about 2.0mM.
190. The insulin preparation according to any one of embodiments 185-189, wherein the insulin compound is present in the amount from about 0.6mM to about 1.2mM.
191. The insulin preparation according to any one of embodiments 185-190, wherein the nicotinic compound is selected from the group consisting of nicotinamide, nicotinic acid, niacin, niacin amide and vitamin B3 and/or salts thereof and/or any combination thereof.
192. The insulin preparation according to any one of embodiments 185-191, wherein the nicotinic compound is nicotinamide.
193. The insulin preparation according to embodiment 192, comprising from about 1mM
to about 250mM of the nicotinic compound.
194. The insulin preparation according to embodiment 192, comprising from about 1mM
to about 250mM of the nicotinic compound.
195. The insulin preparation according to embodiment 192, comprising from about 80mM
to about 230mM of the nicotinic compound.
196. The insulin preparation according to any one of embodiments 185-195, comprising from about 10mM to about 60mM of arginine.
197. The insulin preparation according to any one of embodiments 185-196, comprising from about 10mM to about 30mM of arginine.
198. The insulin preparation according to any one of embodiments 185-197, comprising about 20mM arginine.
199. The insulin preparation according to any one of embodiments 185-198, wherein said buffer is a phosphate buffer.
200. The insulin preparation according to any one of embodiments 185-199, wherein said buffer is Tris.
201. The insulin preparation according to any one of embodiments 185-200, which may further comprises preservative agent(s), isotonicity agent(s) and/or stabilizer(s).
202. The insulin preparation according to any one of embodiments 185-201, which further comprises a metal ion.
203. The insulin preparation according to embodiment 202, wherein the metal ion is zinc.
204. The insulin preparation according to embodiment 203, wherein the zinc:insulin molar ratio is from about 0:6 to about 3.5:6.
205. The insulin preparation according to embodiment 203, wherein the zinc:insulin molar ratio is from about 2:6 to about 3:6.
206. The insulin preparation according to any one of embodiments 185-205, wherein the preparation has a pH of less than 7.4.
207. The insulin preparation according to any one of embodiments 185-205, wherein the preparation has a pH of about 7.4.
208. The insulin preparation according to any one of embodiments 185-205, wherein the preparation has a pH of about 7.1 209. An insulin preparation comprising: B28Asp human insulin; nicotinamide;
zinc; argin-ine; and a phosphate buffer.
210. The insulin preparation of embodiment 209, wherein the B28Asp human insulin is present in a concentration ranging from about 0.6 mM to about 1.2 mM, and wherein the nicotinamide is present at a concentration ranging from about 80 mM to about 260 mM, and wherein the arginine is present in a concentration ranging from about 10 mM to about 40 mM, and wherein less than about 4 zinc ions are present per six B28Asp human insulin molecules, and wherein the preparation has a pH of about 7.4 or less.
211. An insulin preparation consisting essentially of:
a. B28Asp human insulin, wherein the B28Asp human insulin is present in a concentration ranging from about 0.6 mM to about 1.2 mM;
b. Nicotinamide, wherein the nicotinamide is present in a concentration ranging from about 80 mM to abour 260 mM;
c. Zinc, wherein less than about 4 zinc ions are present per six B28Asp human insulin molecules;
d. Arginine, wherein the the arginine is present in a concentration ranging from about 10 mM to about 30 mM; and e. a phosphate buffer;
wherein the preparation has a pH of about 7.1.
212. A method of reducing the blood glucose level in mammals by administering to a mammal in need of such treatment a therapeutically active dose of an insulin preparation according to any one of the preceding embodiments.
5 213. A method for the treatment of diabetes mellitus in a subject comprising administer-ing to a subject an insulin preparation according to any one of embodiments 1-211.
214. An insulin preparation according to any one of embodiments 1-211, for use in the treatment or prevention of hyperglycemia including stress induced hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, and burns, operation wounds and 10 other diseases or injuries where an anabolic effect is needed in the treatment, myocardial infarction, stroke, coronary heart disease and other cardiovascular disorders and treat-ment of critically ill diabetic and non-diabetic patients.
215. An insulin preparation according to any one of embodiments 1-211, for use in the treatment of hyperglycemia type 2 diabetes and type 1 diabetes.
Further embodiments of the invention relate to the following:
216. An insulin preparation comprising:
= an insulin compound, = a nicotinic compound, and = arginine.
217. The insulin preparation according to embodiment 216, wherein the insulin com-pound is human insulin or an insulin analog.
218. The insulin preparation according to embodiments 216-217, wherein the insulin compound is B28Asp human insulin.
219. The insulin preparation according to any one of embodiments 216-218, wherein the insulin compound is B28LysB29Pro human insulin.
220. The insulin preparation according to any one of embodiments 216-219, wherein the insulin compound is B3Ly5B29Glu human insulin.
221. The insulin preparation according to any one of embodiments 216-220, wherein the insulin compound is present in the amount from about 0.2mM to about 2.0mM.
222. The insulin preparation according to any one of embodiments 216-221, wherein the insulin compound is present in the amount from about 0.3mM to about 1.2mM.
223. The insulin preparation according to any one of embodiments 216-222, wherein the nicotinic compound is selected from the group consisting of nicotinamide, nicotinic acid, niacin, niacin amide and vitamin B3 and/or salts thereof and/or any combination thereof.
224. The insulin preparation according to any one of embodiments 216-223, comprising from about 1mM to about 150mM of the nicotinic compound.
225. The insulin preparation according to any one of embodiments 216-224, comprising from about 1mM to about 85mM of arginine.
226. The insulin preparation according to any one of 216-225, which further comprises a metal ion, preservative agent(s), isotonicity agent(s) and stabilizer(s) and buffer(s).
227. A method of reducing the blood glucose level in mammals by administering to a pa-tient in need of such treatment a therapeutically active dose of an insulin preparation ac-cording to any one of embodiments 216-226.
228. A method for the treatment of diabetes mellitus in a subject comprising administer-ing to a subject an insulin preparation according to any one of embodiments 216-226.
229. An insulin preparation according to any one of embodiments 216-226, for use in the treatment or prevention of hyperglycemia including stress induced hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, and burns, operation wounds and other diseases or injuries where an anabolic effect is needed in the treatment, myocardial infarction, stroke, coronary heart disease and other cardiovascular disorders and treat-ment of critically ill diabetic and non-diabetic patients.
The invention is further illustrated by the following examples which are not to be construed as limiting.
All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each refer-ence were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law).
All headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.
The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the inven-tion.
The citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability, and/or enforceability of such patent documents.
This invention includes all modifications and equivalents of the subject matter re-cited in the claims appended hereto as permitted by applicable law.
EXAMPLES
Example 1 Preparation of pharmaceutical preparations The pharmaceutical preparations of the present invention may be formulated as an aqueous solution. The aqueous medium is made isotonic, for example, with sodium chloride or glyc-erol. Furthermore, the aqueous medium may contain zinc ions, for example added as zinc acetate or zinc chloride, buffers and preservatives. Arginine may be added as Arg, HCI. The pH value of the preparation is adjusted to the desired value and may be between about 3 to about 8.5, between about 3 and about 5 or about 6.5 and about 7.5 depending on the isoe-lectric point, pl, of the insulin in question.
Table 1. Composition of insulin preparations according to this invention Insulin Zn Phenol m- NaCI Phos- Tris Glyce- Arginine, Nicotin-Glutamic pH
aspart (mM) (mM) cresol (mM) phate (mM) rol HCI amide acid (mM) (mM) (mM) (%w/v) (mM) (mM) (mM) A* 0.6 0.3 16 16 10 7 1.6 7.4 B 0.6 0.3 16 16 2 7 130 7.4 C 0.6 0.3 16 16 2 7 50 80 50 7.4 D 0.6 0.3 16 16 2 7 130 7.4 E 0.6 0.3 16 16 2 7 50 80 50 7.4 F 0.6 0.3 16 16 20 7 30 80 30 7.4 G 0.6 0.3 16 16 20 7 30 80 30 7.4 H
1.2 0.6 16 16 20 7 30 80 30 7.4 I 1.2 0.6 16 16 20 7 30 80 30 7.4 J 0.6 0.3 16 16 10 7 1.3 80 7.4 K 0.6 0.3 16 16 10 7 0.77 30 80 7.4 L 0.6 0.3 16 16 10 7 0.24 30 80 30 7.4 M 0.6 0.3 16 16 10 7 60 100 7.4 N 0.6 0.3 16 16 10 7 1.13 100 7.4 * Commercially available NovoRapid Table 2. Composition of further insulin preparations according to this invention Preparation [Insulin [Zn2+] [phenol] [Arg] [Gly] [Glu] [His] [Nicotin pH
nr. aspart] mM mM mM mM mM mM amide]
mM mM
1 0.6 0.3 32 260 7.4 2 0.6 0.3 32 10 260 7.4 3 0.6 0.3 32 20 260 7.4 4 0.6 0.3 32 30 260 7.4 0.6 0.3 32 40 260 7.4 6 0.6 0.3 32 50 260 7.4 7 0.6 0.3 32 50 260 7.4 8 0.6 0.3 32 50 260 7.4 9 0.6 0.3 32 50 260 7.4 Table 3. Composition of further insulin preparations according to this invention Preparation [Insulin [Zn2+] [phenol] [m- [Arg] [Glycerol] [tris] [Nicotin pH
nr. aspart] mM mM cresol] mM %w/vol mM amide]
mM mM mM
10 0.6 0.35 16 16 1.3 7 80 7.4 11 0.6 0.35 16 16 10 1.3 7 80 7.4 12 0.6 0.35 16 16 30 1.3 7 80 7.4 13 0.6 0.35 16 16 50 1.3 7 80 7.4 Table 4. Composition of further insulin preparations according to this invention Preparation [Insulin [Zn2+] [phenol] [m- [Arg] [Glycerol]
[Phos- [Nicotin pH
nr. aspart] mM mM mM cresol] mM %w/vol phate]
amide] mM
mM mg/mL
14 0.6 0.30 16 16 20 1.08 3 80 7.1 15 0.6 0.30 16 16 20 - 3 230 7.1 16 0.6 0.20 16 16 20 - 3 230 7.1 17 0.6 0.24 16 16 20 0.24 3 180 7.1 18 0.6 0.28 16 16 20 0.45 3 155 7.1 19 0.6 0.25 16 16 20 0.75 3 120 7.1 20 0.6 0.20 16 16 20 1.08 3 80 7.1 10 Example 2 Analysis of insulin chemical stability Size Exclusion Chromatography Quantitative determination of high molecular weight protein (HMWP) and monomer insulin 15 aspart was performed on Waters insulin (300 x 7.8mm, part nr wat 201549) with an eluent containing 2.5M acetic acid, 4mM L-arginine and 20 %(VN) acetonitrile at a flow rate of 1m1/min. and 40 C. Detection was performed with a tuneable absorbance detector (Waters 486) at 276nm. Injection volume was 40p1 and a 600pM human insulin standard.
HMWP and concentration of the preparations were measured at each sampling point.
Reverse phase chromatography (U PLC) Determination of the insulin aspart related impurities were performed on a UPLC system us-ing a BEH RP 082.1 x 100mm column, particle size of 1,7pm. Waters part no 186002878.
with a flow rate of 0,5m1/min., at 40 C detection at 220nm. Elution was performed with a mobile phase consisting of the following:
A. 10 % (w/V) acetonititrile, 2.8% (w/w) sodium sulphate, 0.3 % (w/w) o-phosphoric acid, pH 3.5.
B. 70 % (w/V) acetonitrile. Gradient: 0-11 min isocratic with 73%/27% of NB, linear change to 52%148% NB, 13-15 min. linear change to 73%/27% of NB, 15-20 min. iso-cratic gradient at 73%/27% of NB.
The amount of B28iso-aspartate, desamido and other related impurities were de-termined as absorbance area measured in percent of total absorbance area determined after elution of the preservatives. The RP-UPLC method is equivalent to the analytical method used for quality control of Novo Nordisk marketed insulin aspart pharmaceuticals.
Addition of arginine reduces the amount of degradation products formed, especially HMWP and des-amido forms, increasing the concentration of arginine in the range 10 to 50mM leads to further reduction of degradation. The physical stability measured as lag time in the ThT assay is reduced upon addition of arginine and is increasingly reduced when the arginine concentration is increased. The overall performance of 50mM arginine is superior to 50 mM glycine, 50mM glutamic acid, or 50mM histidine regarding reduction of the formation of degradation products, as is shown in Table 4 below.
The insulin preparations of the present invention provide fast-acting insulin prepara-tions which are not only physically stable, but surprisingly also chemically stable.
Table 5. Physical and chemical stability data for insulin preparations 1-9 of Table 2 Preparation nr. Physical stabil- Chemical stability ity, lag time Content of degradation product (%) measured as differ-(min) in ThT ence between content after incubation for 2 weeks at assay 37 C and at 4 C
B28 !soAsp des-amido Other re- HMWP
forms lated impuri-ties 1 160 1.17 3.67 1.73 1.36 2 80 1.30 3.05 0.82 0.65 3 80 1.30 2.49 0.64 0.34 4 60 1.31 2.26 0.79 0.20 60 1.27 2.27 0.37 0.19 6 40 1.36 1.99 0.47 0.16 7 100 1.26 4.72 2.21 1.11 8 50 1.39 3.41 1.07 0.70 9 0 1.75 6.99 2.22 1.01 Table 6. Chemical stability data for insulin preparations 10-13 of Table 3 Preparation nr. Chemical stability Content of degradation product (%) measured as differ-ence between content after incubation for 2 weeks at 37 C and at 4 C
B28 !soAsp des-amido Other re- HMWP
forms lated impuri-ties 1.35 1.90 1.71 0.91 11 1.45 1.44 0.98 0.39 12 1.43 1.07 0.75 0.21 13 1.46 0.99 0.84 0.16 Table 7. Physical and chemical stability data for insulin preparations 14-20 of Table 4 Preparation Physical stabil- Chemical stability 5 nr. ity, lag time Content of degradation product ( /0) measured after incu-(min) in ThT bation for 4 weeks at 37 C
assay B28 !soAsp desamido Other related HMWP
forms impurities 14 133 2.7 2.9 2.1 0.4 15 87 2.7 3.6 2.3 0.4 16 50 2.8 4.4 2.7 0.4 17 65 2.7 3.5 2.3 0.4 18 107 2.7 3.3 2.2 0.5 19 85 2.6 3.1 2.3 0.5 20 59 2.6 3.3 2.3 0.5 Example 3 Pharmacokinetic (PK)/ Pharmacodynamic (PD) studies in LYD pig model and plasma analysis assay PK/PD studies in LYD pigs The PK/PD studies were performed on domestic female pigs, LYD cross-breed, weighing between 55 and 110kg. The pigs were catheterised into the jugular vein through an ear vein at least 2 days before start of the study. The last meal before the start of the study was served to the animals approx. 18 hours prior to the injection of the test preparation, and the animals had free access to water at all time during the fasting period and the test period.
At time 0 hours the test preparation was given subcutaneous on the lateral side of the neck.
A blood sample was drawn prior dosing and at regular time intervals after dosing samples were drawn from the catheter and sampled into 1.5m1 glass tubes pre-coated with heparin.
The blood samples were kept in ice water until separation of plasma by centrifugation for 10min. 3000rpm at 4 C, which was done within the first 30 minutes. Plasma samples were stored at 4 C for short time (2-3 hours) or at -18 C for long term storage and were analysed for glucose on YSI or Konelab 30i and for insulin Aspart concentration by LOCI.
Luminescent Oxygen Channeling Immunoassay (LOCI) for Insulin Aspart quantification The insulin Aspart LOCI is a monoclonal antibody-based sandwich immunoassay and ap-plies the proximity of two beads, the europium-coated acceptor beads and the streptavidin coated donor-beads. The acceptor beads were coated with a specific antibody against hu-man insulin and recognize insulin Aspart in plasma samples. A second biotinylated antibody bind specific to insulin Aspart and together with the streptavidin coated beads, they make up the sandwich. Illumination of the beads-aggregate-immunocomplex releases singlet oxygen from the donor beads which channels into the acceptor beads and triggers chemilumines-cence. The chemiluminescence was measured and the amount of light generated is propor-tional to the concentration of insulin Aspart.
Compared to the marketed product NovoRapid , the initial rate of plasma glucose lowering is faster for the preparations of the present invention (Figures 3 and 4).
Likewise, when com-pared to NovoRapid , the initial absorption rate of the insulin component of the preparations of the present invention, is markedly faster (Figure 5).
5 Example 4 General introduction to ThT fibrillation assays for the assessment of physical stability of protein formulations Low physical stability of a peptide may lead to amyloid fibril formation, which is observed as well-ordered, thread-like macromolecular structures in the sample eventually resulting in gel 10 formation. This has traditionally been measured by visual inspection of the sample. However, that kind of measurement is very subjective and depending on the observer.
Therefore, the application of a small molecule indicator probe is much more advantageous.
Thioflavin T
(ThT) is such a probe and has a distinct fluorescence signature when binding to fibrils [Naiki et al. (1989) Anal. Biochem. 177, 244-249; LeVine (1999) Methods. Enzymol.
309, 274-284].
15 The time course for fibril formation can be described by a sigmoidal curve with the following expression [Nielsen et al. (2001) Biochemistry 40, 6036-6046];
f +m ft F = f, + m,t + ________________ ), 1+e t" Eq.(i) 20 Here, F is the ThT fluorescence at the time t. The constant to is the time needed to reach 50% of maximum fluorescence. The two important parameters describing fibril forma-tion are the lag-time calculated by to ¨ 2T and the apparent rate constant kapp =
= = = ==
==
.= = ff + mft c.) c.) - =
o kapp = lit f, H
- f, + mIt =
-111111111111p111111111111 to Ti me Lag-time = to -Formation of a partially folded intermediate of the peptide is suggested as a general initiating mechanism for fibrillation. Few of those intermediates nucleate to form a template onto which further intermediates may assembly and the fibrillation proceeds.
The lag-time corresponds to the interval in which the critical mass of nucleus is built up and the apparent rate constant is the rate with which the fibril itself is formed.
Sample preparation Samples were prepared freshly before each assay. Each sample composition is described in each example. The pH of the sample was adjusted to the desired value using appropriate amounts of concentrated NaOH and HCIator HCI. Thioflavin T was added to the samples from a stock solution in H20 to a final concentration of 1 M.
Sample aliquots of 2000 were placed in a 96 well microtiter plate (Packard Opti-PlateTm-96, white polystyrene). Usually, four or eight replica of each sample (corresponding to one test condition) were placed in one column of wells. The plate was sealed with Scotch Pad (Qiagen).
Incubation and fluorescence measurement Incubation at given temperature, shaking and measurement of the ThT
fluorescence emis-sion were done in a Fluoroskan Ascent FL fluorescence platereader or Varioskan platereader (Thermo Labsystems). The temperature was adjusted to 37 C. The orbital shaking was ad-justed to 960rpm with an amplitude of 1mm in all the presented data.
Fluorescence meas-urement was done using excitation through a 444nm filter and measurement of emission through a 485nm filter.
Each run was initiated by incubating the plate at the assay temperature for 10 min.
The plate was measured every 20 minutes for a desired period of time. Between each meas-urement, the plate was shaken and heated as described.
Data handling The measurement points were saved in Microsoft Excel format for further processing and curve drawing and fitting was performed using GraphPad Prism. The background emission from ThT in the absence of fibrils was negligible. The data points are typically a mean of four or eight samples and shown with standard deviation error bars. Only data obtained in the same experiment (i.e. samples on the same plate) are presented in the same graph ensuring a relative measure of fibrillation between experiments.
The data set may be fitted to Eq. (1). However, since full sigmodial curves are not always achieved during the measurement time, lag times were here visually determined from the ThT fluorescence curve as the time point at which the ThT fluorescence is different than the background level.
Measurement of initial and final concentrations The peptide concentration in each of the tested formulations were measured both before ap-plication in the ThT fibrillation assay ("Initial") and after completion of the ThT fibrillation ("Af-ter ThT assay"). Concentrations were determined by reverse HPLC methods using a pramlin-tide standard as a reference. Before measurement after completion 150p1 was collected from each of the replica and transferred to an Eppendorf tube. These were centrifuged at 30000 G
for 40mins. The supernatants were filtered through a 0.22pm filter before application on the HPLC system.
Claims (32)
1. An insulin preparation comprising:
.cndot. an insulin compound, .cndot. a nicotinic compound, and .cndot. arginine.
.cndot. an insulin compound, .cndot. a nicotinic compound, and .cndot. arginine.
2. The insulin preparation according to claim 1, wherein the insulin compound is human in-sulin or an insulin analog.
3. The insulin preparation according to any one of claims 1 or 2, wherein the insulin com-pound is selected from the group consisting of B28Asp human insulin, B3Ly5B29Glu hu-man insulin and B28LysB29Pro.
4. The insulin preparation according to any one of the preceding claims, wherein the insulin compound is B28Asp human insulin.
5. The insulin preparation according to any one of the preceding claims, wherein the insulin compound is present in the amount from about 0.2mM to about 2.0mM.
6. The insulin preparation according to any of the preceding claims, wherein the insulin compound is present in the amount from about 0.6mM to about 1.2mM.
7. The insulin preparation according to any one of the preceding claims, wherein the nico-tinic compound is selected from the group consisting of nicotinamide, nicotinic acid, nia-cin, niacin amide and vitamin B3 and/or salts thereof and/or any combination thereof.
8. The insulin preparation according to any one of the preceding claims wherein the nico-tinic compound is nicotinamide.
9. The insulin preparation according to any one of the preceding claims, comprising from about 1mM to about 250mM of the nicotinic compound.
10. The insulin preparation according to any one of the preceding claims, comprising from about 1mM to about 250mM of the nicotinic compound.
11. The insulin preparation according to any one of the preceding claims, comprising from about 80mM to about 230mM of the nicotinic compound.
12. The insulin preparation according to any one of the preceding claims, comprising from about 10mM to about 60mM of arginine.
13. The insulin preparation according to any one of the preceding claims, comprising from about 10mM to about 30mM of arginine.
14. The insulin preparation according to any one of the preceding claims, comprising about 20mM arginine.
15. The insulin preparation according to any one of the preceding claims, which further com-prises one or more buffer(s).
16. The insulin preparation according to claim 15, wherein said buffer is a phosphate buffer.
17. The insulin preparation according to claim 15, wherein said buffer is Tris.
18. The insulin preparation according to any one of the preceding claims, which may further comprises preservative agent(s), isotonicity agent(s) and/or stabilizer(s).
19. The insulin preparation according to any one of the preceding claims, which further com-prises a metal ion.
20. The insulin preparation according to claim 19, wherein the metal ion is zinc.
21. The insulin preparation according to claim 20, wherein the zinc:insulin molar ratio is from about 0:6 to about 3.5:6.
22. The insulin preparation according to claim 20, wherein the zinc:insulin molar ratio is from about 2:6 to about 3:6.
23. The insulin preparation according to any one of the preceding claims, wherein the prepa-ration has a pH of less than 7.4.
24. The insulin preparation according to any one of the preceding claims, wherein the prepa-ration has a pH of about 7.4.
25. The insulin preparation according to any one of the preceding claims, wherein the prepa-ration has a pH of about 7.1.
26. An insulin preparation comprising: B28Asp human insulin; nicotinamide;
zinc; arginine;
and a phosphate buffer.
zinc; arginine;
and a phosphate buffer.
27. The insulin preparation of claim 26, wherein the B28Asp human insulin is present in a concentration ranging from about 0.6 mM to about 1.2 mM, and wherein the nicotinamide is present at a concentration ranging from about 80 mM to about 260 mM, and wherein the arginine is present in a concentration ranging from about 10 mM to about 40 mM, and wherein less than about 4 zinc ions are present per six B28Asp human insulin molecules, and wherein the preparation has a pH of about 7.4 or less.
28. An insulin preparation consisting essentially of:
a. B28Asp human insulin, wherein the B28Asp human insulin is present in a concentration ranging from about 0.6 mM to about 1.2 mM;
b. Nicotinamide, wherein the nicotinamide is present in a concentration ranging from about 80 mM to abour 260 mM;
c. Zinc, wherein less than about 4 zinc ions are present per six B28Asp human insulin molecules;
d. Arginine, wherein the the arginine is present in a concentration ranging from about 10 mM to about 30 mM; and e. a phosphate buffer;
wherein the preparation has a pH of about 7.1.
a. B28Asp human insulin, wherein the B28Asp human insulin is present in a concentration ranging from about 0.6 mM to about 1.2 mM;
b. Nicotinamide, wherein the nicotinamide is present in a concentration ranging from about 80 mM to abour 260 mM;
c. Zinc, wherein less than about 4 zinc ions are present per six B28Asp human insulin molecules;
d. Arginine, wherein the the arginine is present in a concentration ranging from about 10 mM to about 30 mM; and e. a phosphate buffer;
wherein the preparation has a pH of about 7.1.
29. A method of reducing the blood glucose level in mammals by administering to a mammal in need of such treatment a therapeutically active dose of an insulin preparation accord-ing to any one of the preceding claims.
30. A method for the treatment of diabetes mellitus in a subject comprising administering to a subject an insulin preparation according to any one of claims 1-28.
31. An insulin preparation according to any one of claims 1-28, for use in the treatment or prevention of hyperglycemia including stress induced hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, and burns, operation wounds and other dis-eases or injuries where an anabolic effect is needed in the treatment, myocardial infarc-tion, stroke, coronary heart disease and other cardiovascular disorders and treatment of critically ill diabetic and non-diabetic patients.
32. The insulin preparation according to claim 31, for use in the treatment of hyperglycemia type 2 diabetes and type 1 diabetes.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10194895 | 2010-12-14 | ||
EP10194895.8 | 2010-12-14 | ||
US201061425378P | 2010-12-21 | 2010-12-21 | |
US61/425,378 | 2010-12-21 | ||
PCT/EP2011/072809 WO2012080362A1 (en) | 2010-12-14 | 2011-12-14 | Preparation comprising insulin, nicotinamide and an amino acid |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2821613A1 true CA2821613A1 (en) | 2012-06-21 |
Family
ID=43857925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2821613A Withdrawn CA2821613A1 (en) | 2010-12-14 | 2011-12-14 | Preparation comprising insulin, nicotinamide and an amino acid |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2651446A1 (en) |
JP (1) | JP2014501239A (en) |
KR (1) | KR20140030125A (en) |
CN (1) | CN103328006A (en) |
AU (1) | AU2011343360A1 (en) |
BR (1) | BR112013014856A2 (en) |
CA (1) | CA2821613A1 (en) |
IL (1) | IL226336A0 (en) |
MX (1) | MX2013006174A (en) |
RU (1) | RU2013130374A (en) |
WO (1) | WO2012080362A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013186138A1 (en) * | 2012-06-14 | 2013-12-19 | Novo Nordisk A/S | Preparation comprising insulin, nicotinamide and arginine |
WO2015131902A1 (en) * | 2014-03-07 | 2015-09-11 | Jørgensen Klavs Holger | Novel fast acting insulin preparations |
JO3624B1 (en) | 2014-05-08 | 2020-08-27 | Lilly Co Eli | ): rapid-acting insulin compositions |
JO3749B1 (en) | 2015-08-27 | 2021-01-31 | Lilly Co Eli | Rapid-acting insulin compositions |
WO2019243627A1 (en) | 2018-06-23 | 2019-12-26 | Adocia | Device for injecting an insulin solution |
FR3083985A1 (en) | 2018-07-23 | 2020-01-24 | Adocia | DEVICE FOR INJECTING AN INSULIN SOLUTION (S) |
FR3083984A1 (en) | 2018-07-23 | 2020-01-24 | Adocia | DEVICE FOR INJECTING AN INSULIN SOLUTION (S) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ199391A (en) | 1981-01-02 | 1985-12-13 | Genentech Inc | Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin |
DK58285D0 (en) | 1984-05-30 | 1985-02-08 | Novo Industri As | PEPTIDES AND MANUFACTURING AND USING THEREOF |
DK336188D0 (en) | 1988-06-20 | 1988-06-20 | Nordisk Gentofte | propeptides |
DK105489D0 (en) | 1989-03-03 | 1989-03-03 | Novo Nordisk As | POLYPEPTIDE |
EP0506792B1 (en) | 1989-12-21 | 1995-05-17 | Novo Nordisk A/S | Insulin preparations containing nicotinic acid or nicotinamide |
WO1995016708A1 (en) | 1993-12-17 | 1995-06-22 | Novo Nordisk A/S | Proinsulin-like compounds |
US6500645B1 (en) | 1994-06-17 | 2002-12-31 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
ZA954983B (en) | 1994-06-17 | 1996-02-14 | Novo Nordisk As | N-terminally extended proteins expressed in yeast |
WO1996010417A1 (en) | 1994-10-04 | 1996-04-11 | Novo Nordisk A/S | PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE |
WO1996034882A1 (en) | 1995-05-05 | 1996-11-07 | Eli Lilly And Company | Single chain insulin with high bioactivity |
EP1283051B1 (en) | 1997-06-13 | 2006-06-14 | Eli Lilly And Company | Stable insulin formulations |
AU2003236201A1 (en) * | 2002-05-07 | 2003-11-11 | Novo Nordisk A/S | Soluble formulations comprising monomeric insulin and acylated insulin |
CN101541830A (en) | 2006-09-22 | 2009-09-23 | 诺沃-诺迪斯克有限公司 | Protease resistant insulin analogues |
US8518668B2 (en) | 2006-09-27 | 2013-08-27 | Novo Nordisk A/S | Method for making maturated insulin polypeptides in a fungal cell |
ES2543705T3 (en) * | 2009-06-26 | 2015-08-21 | Novo Nordisk A/S | Preparation containing insulin, nicotinamide and arginine |
-
2011
- 2011-12-14 CA CA2821613A patent/CA2821613A1/en not_active Withdrawn
- 2011-12-14 WO PCT/EP2011/072809 patent/WO2012080362A1/en active Application Filing
- 2011-12-14 BR BR112013014856A patent/BR112013014856A2/en not_active IP Right Cessation
- 2011-12-14 RU RU2013130374/15A patent/RU2013130374A/en not_active Application Discontinuation
- 2011-12-14 CN CN2011800602960A patent/CN103328006A/en active Pending
- 2011-12-14 KR KR1020137018191A patent/KR20140030125A/en not_active Application Discontinuation
- 2011-12-14 MX MX2013006174A patent/MX2013006174A/en unknown
- 2011-12-14 EP EP11794776.2A patent/EP2651446A1/en not_active Withdrawn
- 2011-12-14 AU AU2011343360A patent/AU2011343360A1/en not_active Withdrawn
- 2011-12-14 JP JP2013543772A patent/JP2014501239A/en not_active Withdrawn
-
2013
- 2013-05-13 IL IL226336A patent/IL226336A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20140030125A (en) | 2014-03-11 |
IL226336A0 (en) | 2013-07-31 |
MX2013006174A (en) | 2013-07-15 |
JP2014501239A (en) | 2014-01-20 |
WO2012080362A1 (en) | 2012-06-21 |
RU2013130374A (en) | 2015-01-20 |
EP2651446A1 (en) | 2013-10-23 |
AU2011343360A1 (en) | 2013-06-06 |
BR112013014856A2 (en) | 2016-10-18 |
CN103328006A (en) | 2013-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2612677T3 (en) | Composition comprising insulin, nicotinamide and arginine | |
US20130331320A1 (en) | Fast-acting insulin in combination with long-acting insulin | |
JP5832439B2 (en) | Pharmaceutical composition comprising a GLP-1 agonist, insulin and methionine | |
JP4800959B2 (en) | Soluble pharmaceutical composition for parenteral administration comprising GLP-1 peptide and short-acting insulin peptide for the treatment of diabetes and bulimia | |
CN1501809B (en) | Chronic treatment regimen using glucagon-like insulinotropic peptides | |
CA2821613A1 (en) | Preparation comprising insulin, nicotinamide and an amino acid | |
WO2013186138A1 (en) | Preparation comprising insulin, nicotinamide and arginine | |
AU2013203134B2 (en) | Preparation comprising insulin, nicotinamide and an amino acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AZWI | Withdrawn application |
Effective date: 20150202 |
|
AZWI | Withdrawn application |
Effective date: 20150202 |